HIF-transcribed p53 chaperones HIF-1α by Madan, Esha et al.
10212–10234 Nucleic Acids Research, 2019, Vol. 47, No. 19 Published online 20 September 2019
doi: 10.1093/nar/gkz766
HIF-transcribed p53 chaperones HIF-1
Esha Madan1, Taylor M. Parker2,†, Christopher J. Pelham3,†, Antonio M. Palma1,†, Maria
L. Peixoto1, Masaki Nagane4, Aliya Chandaria5, Ana R. Toma´s1, Rita Canas-Marques1,
Vanessa Henriques1, Antonio Galzerano1, Joaquim Cabral-Teixeira1,
Karuppaiyah Selvendiran6, Periannan Kuppusamy7, Carlos Carvalho1, Antonio Beltran1,
Eduardo Moreno1, Uttam K. Pati8 and Rajan Gogna 1,*
1Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal, 2Department of Surgery, Simon Cancer
Research Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA, 3Center for Clinical
Pharmacology, Washington University School of Medicine and St. Louis College of Pharmacy, St. Louis, MO 63110,
USA, 4Department of Biochemistry, School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku,
Sagamihara, Kanagawa, 252-5201, Japan, 5Biosciences unit, College of Life and Environmental Sciences, University
of Exeter, Stocker Road Exeter EX4 4QD, UK, 6Division of Gynecologic Oncology, Comprehensive Cancer Center,
The Ohio State University Wexner Medical Center, Columbus, OH, USA, 7Department of Radiology and Medicine,
601 Rubin Building, Norris Cotton Cancer Center, Geisel School of Medicine, Dartmouth College, 1 Medical Center
Drive, Lebanon, NH 03756, USA and 8Transcription and Human Biology Laboratory, School of Biotechnology,
Jawaharlal Nehru University, New Delhi 110067, India
Received February 14, 2019; Revised August 14, 2019; Editorial Decision August 15, 2019; Accepted September 02, 2019
ABSTRACT
Chronic hypoxia is associated with a variety of phys-
iological conditions such as rheumatoid arthritis,
ischemia/reperfusion injury, stroke, diabetic vascu-
lopathy, epilepsy and cancer. At the molecular level,
hypoxia manifests its effects via activation of HIF-
dependent transcription. On the other hand, an im-
portant transcription factor p53, which controls a
myriad of biological functions, is rendered transcrip-
tionally inactive under hypoxic conditions. p53 and
HIF-1 are known to share a mysterious relation-
ship and play an ambiguous role in the regulation of
hypoxia-induced cellular changes. Here we demon-
strate a novel pathway where HIF-1 transcription-
ally upregulates both WT and MT p53 by binding
to five response elements in p53 promoter. In hy-
poxic cells, this HIF-1-induced p53 is transcription-
ally inefficient but is abundantly available for protein-
protein interactions. Further, both WT and MT p53
proteins bind and chaperone HIF-1 to stabilize its
binding at its downstream DNA response elements.
This p53-induced chaperoning of HIF-1 increases
synthesis of HIF-regulated genes and thus the effi-
ciency of hypoxia-induced molecular changes. This
basic biology finding has important implications not
only in the design of anti-cancer strategies but also
for other physiological conditions where hypoxia re-
sults in disease manifestation.
INTRODUCTION
Hypoxia is a physiologically relevant biological stress that
regulates organ development (1,2), homeostasis (3), wound
healing (4,5), stroke (6,7) and cancer (2,8–19). Hypoxia in-
duces transcriptional and molecular alterations which pro-
mote cell survival and growth under low oxygen conditions,
by inducing gene expression programs controlling glucose
uptake (20,21), metabolism (22–24), angiogenesis (25,26),
erythropoiesis (27), cell proliferation (28), differentiation
(29) and apoptosis (30).
Tumor hypoxia activates hypoxia-inducible factor (HIF).
HIF molecular network is an important contributor to-
wards cancer progression, and a variety of methods are
adapted to block this pathway to achieve therapeutic utility
(31–35). HIF proteins are transcription factors composed
of an alpha subunit which is specifically stabilized in hy-
poxic conditions and a constitutively expressed -subunit
(ARNT) (36,37), which associates with the alpha subunit.
Three HIF paralogs have been identified, HIF-1, HIF-
2 and HIF-3 (38–40), each with distinct functions in hy-
poxia. HIF-1 and HIF-2 display high structural similar-
ity in their DNA binding domains, but differ in their trans-
activation domains, indicating unique downstream gene
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targets (40–43). HIF-1 has been shown to regulate genes
involved in angiogenesis, most notably VEGF (41), as well
as glycolysis (42), whereas HIF-2 has been shown to pref-
erentially activate genes involved in stem cell maintenance
and invasion (40). HIF-1 and HIF-2 also differ in their
hypoxic induction pattern.HIF-1 protein levels are consis-
tently detected rapidly within the first 2 h following hypoxia,
whereas HIF-2 protein levels are detected later within 72
h post hypoxia exposure (42,43) HIF-3 differs in structure
and acts as a negative regulator of HIF-1 and HIF-2 by
competing with them for the availability of HIF -subunits
(44,45).
Another important transcription factor that regulates a
myriad of cellular functions, including cell cycle, DNA re-
pair, apoptosis, and metabolism, is tumor suppressor p53
(46,47). The TP53 gene is mutated in nearly 50% of cancers,
which frequently results in the full-length protein with in-
creased stability, altered protein conformation and distinct
biological activity from that of WT p53 protein (48). Re-
gardless of the genetic status of p53, WT p53 is known to
adopt a mutant-like conformation during the normal pro-
gression of the cell cycle (49) or by mitogenic stimulation
(50), and most notably, within the hypoxic core of solid tu-
mors (11). Given the altered conformation, MT, and MT-
like p53 can be detected by a mutant conformation-specific
polyclonal antibody, pAb240 (51). MT p53 is known to lose
WT tumor-suppressive properties, butmay also subvertWT
p53 by exerting a dominant-negative effect on the remaining
WT p53 via formation of inactivating co-aggregates (52).
Additionally, MT gain of function (GOF) p53 is known
to gain oncogenic functions and enhance tumor growth
(48,53).
The role and activity of p53 under hypoxia are unclear
(8,54–56), and the relationship between HIF-1 and p53
is ambiguous (8,16,41,57–60). p53 and HIF-1 are known
to bind directly via the oxygen-dependent degradation do-
main of HIF-1 in vitro, as HIF-1 exists as an unfolded
protein and becomes an easy target for protein-protein in-
teraction with p53 (61,62). Such interactions with WT p53
are also found in MCF-7 cells carrying WT p53 (13) and in
MT p53 cells (60). There are conflicting reports on the ac-
cumulation of p53 under hypoxic conditions and whether
onlyMT, or WT or both forms of p53 protein show nuclear
accumulation under hypoxia (8,10,54,55,60).We and others
have found the accumulation of WT p53 under chronic hy-
poxia (58,63). Severe hypoxia or anoxia (<0.2% O2) or the
use of chemical agents result in the activation of p53, which
can, in turn, lead to rapid apoptosis. In contrast, we along
with others have reported that chronic hypoxia-induced p53
has little or no transcriptional capabilities and that hypoxic
p53 loses key post-translational modifications which result
in a transcriptionally inactive, conformational mutant phe-
notype for both WT and MT p53 molecules under physio-
logically relevant hypoxia of 1.8% O2 (11,54,63,64). Thus,
p53 was found to be both responsible and indispensable for
apoptosis under hypoxia (8,12,65–71). It is likely that the
use of random oxygen concentrations ranging from anoxia
to 5% O2, use of chemical stimulants for hypoxia and de-
gree of reoxygenation, are possible reasons for these incon-
sistencies. There has been a lot of confusion about what
definition of biological hypoxia (21,72–75) and under what
conditions in vitro culture experiments should be performed
to mimic physiologically relevant hypoxia (76). Many stud-
ies are performed using chemical stabilizers of HIF such as
cobalt chloride (60,77–79) and deferoxamine (80,81), or un-
der totally anoxic, i.e. 0% O2 conditions (82,83) which are
far from oxygen levels available in various diseases. Results
from such variable conditions add to themisunderstandings
and confusion in the field. Non-invasive electron paramag-
netic resonance (EPR)-assisted measurement of oxygen in
solid tumors shows that tumor oxygen concentration varies
between 1.4% and 2% O2 (63,72,84).
Because both HIF-1 and p53 are major transcription
factors, and hypoxia is an essential and unavoidable phys-
iological menace, it is necessary that a careful molecular
study is performed under control settings using physiologi-
cally relevant hypoxia. This is the reason we have carefully
based this study on measurement and simulation of physio-
logical hypoxia using an EPR-based non-invasive technol-
ogy in human xenografts and tumors in large animals such
as rabbit.
In this study, we have used cancer as the physiological
disease model to study HIF-1-p53 relation. We present a
newly discovered and biologically unavoidable role of both
MT andWT p53 as tumor promoters in the hypoxic regions
of solid tumors. HIF-1, which is activated under hypoxia,
induces p53 expression by directly binding to five response
elements in p53 promoter. HIF-1-inducedWT or MT p53
protein attains a transcriptionally inactive form under phys-
iologically relevant hypoxia and forms a complex withHIF-
1. We found that bothWT andMT p53 interact withHIF-
1 and that HIF-1-p53 complex remains functional while
HIF-1 binds to the response elements (HREs) of its down-
stream target genes. In this complex p53 serves as a molec-
ular chaperone for HIF-1, it stabilizes HIF-1 and pro-
motes its binding to the DNA response elements. This p53-
assisted chaperoning of HIF-1 enhances HIF transcrip-
tional activity thereby increasing the expression of HIF-
regulated genes that contribute to hypoxia-induced growth
and survival.
MATERIALS AND METHODS
Cell lines and culture conditions
p53 WT cancer cells including A375, IM-9, HepG2,
SKCO-1, HeLa, MCF-7, U-87-MG, LNCaP-FGC, NCI-
H711, HCT116, U2OS and p53 MT cancer cells includ-
ing MDA-MB-468, MOLT4, SW837, NCI-H23, P3HR1,
PSN1, SKLMS1, SKLU1, SK-UT-1 and SNU-16 lines
were procured from ATCC (VA, USA). HEK293T cells
were procured from Cell BioLabs Inc. (San Diego, CA) and
HEK293FT cells were procured by Thermo Fisher Scien-
tific (MA, USA). Briefly, the cells were cultured in mono-
layer in respective growth mediums (Dulbecco’s modified
Eagle’s medium (DMEM) or RPMI 1640) supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (FBS)
and antibiotics (1% penicillin/streptomycin) and incubated
under normoxic conditions at 37◦C in a humidified atmo-
sphere of 95% air and 5% CO2.
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Chemicals and constructs
Reagents including Lipofectamine® 3000 transfection
reagent, Superscript Vilo cDNA synthesis kit, PowerUp
SYBR Greenmaster mix, and DAB substrate kit were
purchased from Thermo Fisher Scientific (MA, USA).
MISSION Lentivirus Packaging Mix, human p53 and
HIF-1α shRNA (SHCLNG -NM 000546 and SHCLNG-
NM 001530 respectively) lentiviral plasmid kit used for cell
culture studies and hematoxylin and eosin stain were pur-
chased from Sigma (CA, USA).HIF-1α lentiviral construct
in EX-I0867-Lv105 vector was procured fromGenecopoeia
(MD, USA) and WT p53 or MT (R175H) p53 lentivi-
ral expression vectors were used as described previously
(85) and procured from Addgene (MA, USA). ViraSafe™
(Pantropic) Lentiviral Packaging System were purchased
from Cell BioLabs (CA, USA). Antibodies used for IHC,
anti-HIF1 (Rabbit monoclonal antibody to HIF-1, AC-
0108RUO), anti-p53 (Mouse monoclonal antibody to p53,
P5813) and anti-Histone H3 (Rabbit polyclonal antibody
to Histone H3, ab1791) were procured from Milipore-
Sigma (CA, USA), Sigma-Aldrich (MO, USA) and Ab-
cam (Cambrige, UK) respectively. Antibodies for western
blot and immunoprecipitation anti-HIF1 (Mouse mono-
clonal antibody to HIF-1, ab16066), anti-HIF1 (Mouse
monoclonal antibody to HIF-1, ab2771), anti-RNA poly-
merase II (Goat polyclonal antibody to RNA polymerase
II, ab140509) and anti--Tubulin (Mouse monoclonal anti-
body to -Tubulin, ab40742) were procured from Abcam,
anti-p53 wild-type (Mouse monoclonal antibody to WT-
p53, OP33) and anti-p53 mutant (Mouse monoclonal an-
tibody to MT-p53, OP29L) were procured from Sigma-
Aldrich, anti-p53 (Rabbit monoclonal antibody to p53,
#2527) was procured fromCell Signaling Technology (MA,
USA), anti-RNAse H II (Mouse monoclonal antibody to
RNAse H II, sc-515475) and anti- actin (mouse mono-
clonal antibody to -actin, sc-517582) were procured from
Santa-Cruz Biotechnology (TX,USA). Secondary antibod-
ies anti-Mouse (Goat polyclonal secondary antibody to
Mouse IgG - H&L (HRP), pre-adsorbed, ab97040), anti-
Rabbit (Goat polyclonal secondary antibody to Rabbit IgG
- H&L (HRP), pre-adsorbed, ab7090) and anti-goat (rabbit
polyclonal secondary antibody to goat IgG - H&L (HRP),
pre-adsorbed, ab97105) were procured from Abcam. Pure-
Link RNA Mini Kit and RNeasy FFPE Kit were pro-
cured from Qiagen (CA, USA). Total protein extraction
kit was purchased from Millipore (MA, USA). For lu-
ciferase reporter assay: five putative hypoxia-responsive el-
ements (HREs) containing HIF-1-binding consensus se-
quence 5′-R/CGTG -3′ (86) in the promoter region of
p53;VEGF-HRE; p21-5′-DBS;EPO-HRE;GAL4;WT-p53
GAL4; MT-p53 GAL4 and p53 10kb promoter were cloned
in pGL4 luciferase vector purchased from Promega (WI,
USA).
Gene silencing and overexpression
All work with lentiviruses was performed under BL2/BSL-
2 conditions. Lentiviral production was performed using
HEK293T cells. In brief, 2 × 104 cells per well in 96-well
plate (supplementedwith 10% fetal bovine serum and 4mM
L-glutamine, were allowed to grow overnight. HEK293T
cells were transfected using Lipofectamine® 3000 per man-
ufacturer instructions. Lentiviral supernatant was collected
starting from 24–72 h post-transfection, filtered through
a 0.45 m filter and concentrated by ultracentrifugation.
Titer of virus particles was determined using p24 ELISA
(Cell BioLabs) as per the manufacturer’s protocol, and a
titer of 109 TU/ml was used for cell culture experiments.
Target cells were infected with lentiviral supernatant con-
taining 5 g/ml of polybrene for 24 h. For the knockdown
of both WT and MT p53 (SHCLNG-NM 000546) and
knockdown of HIF-1α shRNA (SHCLNG-NM 001530)
lentiviral plasmid kit was procured from Sigma (CA, USA).
For overexpression of HIF-1α, target cells were infected
with lentiviral particles encoding withHIF-1α cDNA, EX-
I0867-Lv105 vector, Genecopoeia (MD, USA).
Patient samples
For IHC staining, qPCR, ChIP and IPP studies,
formaldehyde-fixed and paraffin-embedded and fresh
frozen cancer tissue samples, including prostate, pancre-
atic, kidney, ovarian, colon, breast, lung and liver cancers,
were procured from the Champalimaud Foundation,
Lisbon, Portugal and Department of Pathology, UAMS,
Little Rock, AR, USA.
Cycloheximide (CHX) chase assay
The half-life of HIF was measured using CHX chase assay.
Approximately, 3 × 105 cells were seeded in 60 mm dishes
and grown for 24 h. Then, the cells were cultured under hy-
poxia (1.8%O2) for 24 h and treated with CHX (100g/ml)
for 0, 3 and 6 h. The cells were collected at the indicated time
points, and total protein lysates were prepared for western
blotting to detect HIF-1.
Immunohistochemistry
Champalimaud Foundation has a well-defined tissue bank-
ing protocol in which representative fresh samples from the
tumor are stored immediately after gross sectioning, often
< 1 h after the specimen is resected, in order to minimize
protein degradation. Representative sections of the tumor
were selected by expert pathologists, to analyze the expres-
sion ofHIF-1 and p53 proteins immunohistochemically in
paraffin-embedded tumor specimens fixed in 4% buffered
formalin. Histological slides with 4 m in thickness, were
deparaffinized in xylol. Slides were heated in 0.01 M cit-
rate buffer for 16 min in a microwave oven. After cool-
ing for 20 min and washing in PBS, endogenous peroxi-
dase was blocked with methanol containing 0.3% hydro-
gen peroxide for 30 min, followed by incubation with PBS
containing 10% normal goat serum for 30 min. For im-
munohistochemical detection of HIF-1, specimens were
incubated overnight at 4◦C with anti-HIF-1 at a dilution
of 1:500. Visualization of bound antibodies was performed
with streptavidin-biotin-peroxidase complex technique (Su-
per Sensitive kit; BioGenex, CA, USA). As a chromogen, 3-
amino-9-ethylcarbazole (BioGenex) was used. Expression
of p53 was investigated with using a standard protocol (87).
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In-vivo ELISA
The in-vivo ELISA was performed as described previously
(88). Briefly, the wells of a PVCmicrotiter plate were coated
with p53 WT or p53 MT antibodies at a concentration of
1–10 g/ml in carbonate/bicarbonate buffer (pH 7.4). The
plate was covered with an adhesive plastic and incubated
overnight at 4◦C. Next, the coating solution was removed,
and the plate was washed twice with 200 l PBS. Antibody-
coated wells were blocked using 200 l blocking buffer, 5%
nonfat dry milk/PBS, and incubated overnight at 4◦C. 5 ×
104 cells were added to each well and incubated for 90 min
at 37◦C. 100 l (0.5 g/100 l) of diluted detection anti-
body p53WT or p53MT was added to each well. The plate
was covered with an adhesive plastic and incubated for 2
h at room temperature, then washed four times with PBS.
100 l of secondary antibody conjugated with horseradish
peroxidase (HRP) was added to the plate. The plate was
covered with an adhesive plastic and incubated for 1–2 h
at room temperature. The plate was washed four times with
PBS, and O.D. was measured using ELISA reader.
RNA isolation and quantitative PCR (qPCR)
Total RNA from cell lines; and laser dissected pa-
tient cancer samples (hypoxic and normoxic zones)
was isolated using the PureLink RNA Mini kit and
RNeasy FFPE Kit, respectively. 10 ng of total RNA
was reverse-transcribed to cDNA using Superscript Vilo
cDNA synthesis kit. Real-time PCR (qPCR) was per-
formed using a BioRad CFX96 and PowerUp SYBR
Green master mix (Thermo Fisher Scientific). The fol-
lowing primers were used for the study: p53 forward,
5′-ACCTATGGAAACTACTTCCTGAAA-3′ and re-
verse, 5′-CTGGCATTCTGGGAGCTTCA-3′; HIF-1α
forward, 5′-CATAAAGTCTGCAACATGGAAGGT-3′
and reverse, 5′-ATTTGATGGGTGAGGAATGGGTT-3′;
GAPDH forward, 5′-GGATGCAGGGAT GATGTTC-3′
and reverse, 5′-TGCACCACCAACTGCTTAG-3′. All
reactions were set up in triplicates. Relative mRNA quan-
tification was obtained using the comparative Ct method
(Ct), and GAPDH served as an internal control, as
described previously (89).
Hypoxia exposure
For hypoxic exposure, p53 WT (A375. IM-9, HepG2,
SKCO-1, HeLa, MCF-7, U-87-MG, LNCaP-FGC, NCI-
H711, HCT116) and p53 MT (MDA-MB-468, MOLT4,
SW837, NCI-H23, P3HR1, PSN1, SKLMS1, SKLU1, SK-
UT-1, SNU-16) cancer cells were placed into a humidified
chamber maintained at 1.8% O2 and 5% CO2 (balance N2)
for 48 h, as described previously (11,63,90). As a control,
cells were cultured in a standard incubator (normoxia; air
with 5% CO2).
In vitro transcription
In-vitro transcription reactions were carried out essentially
as described previously (85,91,92), using 50 ng of G-less
DNA templates. Nuclear extracts from the desired cell lines
and template DNA were pre-incubated at room tempera-
ture for 10 min before nucleotides were added to the mix-
ture. Reaction mixtures (20 l) contained 2.5 mM NaF,
0.5 mM orthovanadate, 10 mM HEPES (pH 7.9), 12 mM
Tris (pH 8.0), 0.1 mM EDTA, 12% glycerol, 60 mM KCl,
5 mM MgCl 2, 0.5 mM ATP, 0.5 mM UTP, 20 M CTP,
0.25mMO-methyl-GTP and 5mMcreatine phosphate. The
DNA template contains six HIF-1 DNA binding sites at
VEGF gene promoter upstream of the adenovirus major
late (AdML) core promoter (92), a transcription initiation
signal attached to a G-less cassette, a poly A signal, and
finally a stop signal (CCT). The quantitative detection of
the transcripts is done by conversion of the transcript to a
cDNA form, using poly T primers, followed by qPCR using
extension primers.
Immunoprecipitation (IP)
Immunoprecipitation experiments were performed as de-
scribed previously (93). Briefly, nuclear extracts from can-
cer cells (WT, p53 KO and HIF-1α KO) and tumor tissue
samples (prostate, breast, kidney, lung, colon, liver, ovar-
ian and pancreatic) were prepared using NE-PER Nuclear
and Cytoplasmic Extraction Reagents (Thermo Fisher Sci-
entific) using the provided protocol. Nuclear extracts were
precleared for 1 h with Protein G PLUS-Agarose beads
(Sigma). IP was then performed with 5g of anti-p53 an-
tibody or HIF-1 antibody on ice for 2 h. Then 10 l of
Protein G PLUS-agarose was added to the lysate and fur-
ther incubated at 4◦C for 4 h. Beads were washed three times
in wash buffer (Nonidet P40 buffer: [20 mM Tris/HCl, pH
7.4, 100 mMNaCl, 10% (v/v) glycerol, 1.0% (v/v) Nonidet
P40 and 1 mMEDTA]). Beads were then boiled at 95◦C for
10 min in 2× SDS loading buffer.
Please refer to Supplementary file for detailed methods
section.
RESULTS
HIF-1 correlates with WT and MT p53 expression in hy-
poxic cells and human tumors
p53 mRNA and protein expression are increased in
hypoxic-cultured cells in relation to HIF-1 (13,54,64,94).
We envisaged if these observations from in vitro setting hold
true in physiologically relevant hypoxia observed in human
tumors and whether expression of HIF-1 within intra-
tumoral regions impacts p53 expression. Pancreatic (Fig-
ure 1A, top panel) and kidney (Figure 1A, bottom panel)
cancer samples (FFPE) were H&E and immuno-stained for
HIF-1 and p53 expression. Ten different areas, as demon-
strated by rectangular boxes within each tumor, represent-
ing variability in HIF-1 expression, were selected (Fig-
ure 1A). These selected areas with variable HIF-1 expres-
sion are zoomed below each tumor. Signal intensity anal-
ysis points towards a positive dependent-relation between
HIF-1 and p53 expression. Immunostaining for Histone
H3 (a nuclear protein, like HIF-1 and p53) was performed
as a control to quantify the variations in the expression of
HIF-1 and p53 expression. No variations in Histone H3
staining (compared with HIF-1 and p53 expression) were
observed in pancreatic and kidney cancer samples.
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Figure 1. HIF-1 correlates with p53 expression in hypoxic zones of human cancers. (A) Immunohistochemical staining for p53 and HIF-1 shows their
distribution in ten different regions of pancreatic and kidney tumors. The HIF-1 expression shows great intra-tumoral heterogeneity within the hypoxic
microenvironment of both cancers. Ten fields marked 1–10 with variable HIF-1 expression were selected, and p53 expression in such areas was observed.
A zoomed view (40×) of each of these ten fields shows high-resolution staining for HIF-1 and p53, H&E staining is used to locate the general structure
of the tumor tissue. IHC with Histone H3 is used as control. (B) qPCR analysis was used to observe p53 and HIF-1α gene expression in the ten selected
regions, as shown in figure A. These 10 hypoxic regions were laser-captured, and gene expression was analyzed in triplicate. Normoxic regions were defined
by negative HIF-1 staining; 5 such sites were selected, and gene expression was analyzed in triplicate. Blue and red arrows point towards easily observable
trends for a simultaneous increase and decrease in HIF-1α and p53 expression, respectively. (C) Box plots present collective data from 10 different areas
and analyzed in triplicates in figure B and show increased expression of both p53 (red) andHIF-1α (blue) in ten heterogeneous areas from single pancreatic
and kidney cancer. Correlation coefficient analysis reveals R2 = 0.6247 and R2 = 0.0882 for pancreatic and kidney cancer, respectively (n = 10 for hypoxic
regions, n = 5 for normoxic regions; all samples were analyzed in triplicates). Two-sided Student’s t-test was used for analysis; all P values are labeled on
the figure.
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To quantify this relationship, these ten areas from pan-
creatic and kidney tumors were laser-captured and ana-
lyzed for the expression of HIF-1α and p53 by qPCR (Fig-
ure 1B and C). Each laser-captured tissue section was ana-
lyzed in triplicates. For each tumor, five areas were selected
and laser-captured to represent normoxia, which was de-
fined by the absence of HIF-1α signal. In Figure 1B, ex-
pressions of HIF-1α and p53 are represented within each
rectangular area selection fromFigure 1A. This provides an
opportunity to see quantitativemRNAexpression as well as
protein expression (Supplementary Figure S1), for each se-
lected area in both tumors. The correlation between the ex-
pression ofHIF-1 and p53 is a bit weak at the protein level,
possibly due to control of protein degradation rate, which
is strongly relevant to HIF-1. Normoxic regions showed
lack of HIF-1α expression, but robust p53 expression. In
the hypoxic areas of both kidney and pancreatic tumors,
HIF-1α was upregulated, although, the extent of upregu-
lation varied between the examined sites. Additionally, p53
expression significantly increased overall in hypoxic regions
in both kidney and pancreatic tumors. Interestingly,HIF-1α
and p53 showed similar trends in expression in the ten ex-
amined sites. The arrows in Figure 1B, point towards such
correlation; sites with strong and diffuse HIF-1α signal co-
incide with robust p53 expression whereas sites with mod-
erate or lowHIF-1  show lower p53 signal. Next, we deter-
mined the correlation between HIF-1α and p53 expression
under hypoxic and normoxic conditions (Figure 1C). In hy-
poxic regions, the data showed a strong positive correlation
between the expression of HIF-1α and p53 in a highly con-
trolled setting as samples represent heterogeneous regions
of the same tumor of pancreatic origin (R2 and P values are
labeled on the figure). In kidney cancer sample, although
p53 was upregulated in hypoxic regions, a strong correla-
tion between p53 and HIF-1α expression was not observed
(R2 = 0.0513).
We further expanded our p53-HIF-1α correlation analy-
sis in a variety of human tumors including that of pancreas,
kidney, colon, breast, lung, and liver (three patients for each
tumor, analyzed in triplicates) (Figure 2A). Similar trends
across all cancer types were identified, with the exception
of lung cancer where the correlation between expression of
HIF-1α and p53 was weak (R2 = 0.1082). Expression of
HIF-1α is poor, but p53 is robust in normoxic regions of
the tumor. However, in the hypoxic regions, both HIF-1α
and p53 expressions are significantly higher. A strong cor-
relation between HIF-1α and p53 expression is observed in
this large sample study from multiple cancers. Since p53 is
mutated in more than 50% tumors (95–97), we determined
if the mutational status of p53 has any impact on this ob-
served correlation between HIF-1α and p53 expression in
hypoxic cell culture.
To arrive at a physiologically relevant hypoxia condi-
tion which should be used to culture the cell lines, we have
used data from an ongoing clinical trial managed by our
group and collaborators; please refer to the trial listing
(https://clinicaltrials.gov/ct2/show/NCT02706197). Oxygen
measurement data using state of the art non-invasive EPR
spectroscopy (11) in 24 patients of breast cancer, squamous
cell carcinoma and pancreatic ductal adenocarcinoma (un-
published data from the clinical trial), combined with our
data in past using non-invasive electron paramagnetic reso-
nance (EPR)-assisted measurement of oxygen in solid tu-
mors shows that tumor oxygen concentration varies be-
tween 1.4% and 2%O2 (63,72,84). Oxygenmeasurements by
other groups in clinical cancer samples have also reported
that oxygen concentration is around 1.7, 1.5, 1.2, 1.3, 2.2
and 1.8% O2 for brain, breast, cervical, renal, non-small-
cell lung cancer and rectal cancer, respectively (72). Based
on these findings, all hypoxia culture was established at this
oxygen value (1.8% O2). Ten p53 wild-type (WT) and mu-
tant (MT) cancer cell lines were cultured under hypoxic con-
ditions. The in vitro results were similar to our observations
in human clinical cancers; hypoxia led to an increase of both
p53 andHIF-1α expressions (Figure 2B and C) exhibiting a
strong correlation between their expressions (Figure 2B).
HIF-1 regulates p53 expression in hypoxic cancer cells
Results from human tumors and cultured cells suggested a
strong relationship between HIF-1 and p53 expressions.
We next determined whether genetic manipulation of HIF-
1α can achieve alterations in p53 expression (Figure 3A and
B). Five p53WT and five p53MT cancer cell lines were cul-
tured under normoxic and hypoxic conditions. Empty back-
bone vectors and scrambled shRNAs were used as transfec-
tion controls and had no significant impact on gene expres-
sion (box plots 5, 6, 9, 10). Hypoxia-induced expression of
bothHIF-1α and p53when comparedwith normoxic condi-
tions (compare box plots 1 & 2 with 3 & 4).HIF-1α shRNA
reduced HIF-1α expression, but it also resulted in a signifi-
cant reduction of p53 expression in both WT and MT cells
(box plots 7 & 8). The efficiency ofHIF-1α and p53 knock-
down by shRNA is shown by Western blot (Figure 3A, in-
set). Exogenous addition of HIF-1α resulted in a signifi-
cant increase in p53mRNA expression (box plots 11 & 12).
These results suggest that HIF-1 can regulate p53 expres-
sion. To more thoroughly investigate HIF-1 genetic regu-
lation of p53, we generated Crispr-assisted HIF-1α knock-
out (KO) MCF-7 cells (which carry a WT p53) andHIF-1α
KO PSN1 cells (which carry MT p53) (Figure 3C). InHIF-
KO (orHIF-1α−/−), hypoxia failed to stimulate p53 expres-
sion; however, incremental treatmentwithHIF-1α cDNA in
hypoxic-cultured MCF-7 and PSN1 cells rescued p53 gene
expression in aHIF-1α dose-dependentmanner (lanes 3–6).
In a western blot experiment, effect of HIF-1 on p53 pro-
tein expression was observed (Figure 3D). NormoxicMCF-
7 and PSN1 cells show no HIF-1 expression and low p53
expression in both HIF-1α WT and KO lines (lanes 1 & 2).
Hypoxia increases the expression of HIF-1 in theWT line,
but KO line shows no expression of HIF-1 (lane 3 & 4).
However, with the hypoxia-induced increase in HIF-1 ex-
pression p53 expression also increases but only in the WT
line, in the HIF-1α KO line no such effect is observed both
inWT (MCF-7) orMT (PSN1) p53 (Figure 3D). In another
western blotting experiment, the effect of a dose-dependent
increase inHIF-1α was observed on the expression of p53 in
both normoxic and hypoxic HIF-1α WTMCF-7 and HIF-
1α KOMCF-7 cells (Figure 3E). Under the normoxic con-
dition, HIF-1 expression is not observed in both WT and
KO MCF-7 cells and dose-dependent exogenous addition
ofHIF-1α also does not result in the expression of HIF-1
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Figure 2. HIF-1 correlates with bothWT andMT p53 in hypoxic cells and hypoxic cancer tissues. (A) Box plots represent qRT-PCR-based quantification
of p53 andHIF-1α gene expression in laser-captured hypoxic and normoxic regions of 6 different cancer types. For each cancer type, three different patient
samples were collected, and from each sample, three different normoxic or hypoxic region were selected, thus for each cancer, three collected samples were
analyzed in triplicates. The correlation coefficient betweenHIF-1α and p53mRNA expression was calculated for each cancer, and R2 values are presented
in the plots. Two-sided Student’s t-test was used for analysis; all P values are labeled on the figure. (B) p53 and HIF-1α gene expressions were quantified
by qRT-PCR analysis from a panel of 10 WT p53 and 10 MT p53 cell lines (listed in 2C) cultured under normoxia or exposed to hypoxia (1.8% O2) for 24
h. For each cell line, gene expression was analyzed on three independent replicates per p53WT or p53MT cell lines. Correlation coefficient analysis shows
a positive correlation between HIF-1α and p53 expression in MT p53 and WT p53 cell lines. Two-sided Student’s t-test was used for analysis; all P values
are labeled on the figure. (C) Heat map depicts p53 and HIF-1α gene expression under normoxia and hypoxia for each WT p53 and MT p53 cancer cell
line (quantified in 2C). HIF-1α and p53 expression increased in all cell lines under hypoxia, irrespective of p53 status. In this figure, each block represents
the values from a gradient scale of low (red), medium (yellow) and high (blue) level of expression.
(lane 1–5). p53 expression in these cells also does not show
any significant variation, and dose-dependent increase in
HIF-1α does not increase p53 expression under normoxic
conditions (lanes 1–5). HIF-1α WT MCF-7 cells show up-
regulation of HIF-1 under hypoxic conditions, which also
results in a significant increase in p53 expression (lane 6),
this increase in p53 expression is reversed in HIF-1α KO
MCF-7 cells cultured under hypoxic conditions, along with
no expression of HIF-1 in the HIF-1α KO line (lane 7).
Dose-dependent exogenous addition of HIF-1α in HIF-1α
KO MCF-7 cells results in upregulation of both HIF-1
and p53 in a dose-dependentmanner (lanes 8–10). This data
shows that HIF-1 regulates p53 expression in hypoxic can-
cer cells.
HIF-1 transcriptionally regulates p53
Collectively, these findings suggest that hypoxia-stimulated
HIF-1 regulates p53 expression at the transcriptional level.
To further dissect this effect, we analyzed the activity of the
full-length p53 promoter (10kb; cloned in pGL4 luciferase
vector) under the influence of HIF-1 (Figure 4A). Beta-
galactosidase and empty pGL4 backbone vectors were used
throughout the study in every luciferase assay as normal-
ization controls. Since we are observing the impact of HIF-
1 in transcriptional regulation of the p53 promoter, we in-
cluded VEGF HIF response element (HRE) luciferase vec-
tor as a positive control of HIF-1 activity given thatVEGF
is a well-characterized target gene of HIF-1 under hypoxia
(98). As expected, inWT p53MCF-7 cells under normoxia,
VEGFHRE vector showed poor activity, which is expected
because of poor HIF-1 expression (bar 3). The p53 10kb
promoter was active in normoxia, and HIF-1α shRNA did
not impact this activity (bars 5 & 6). p53 downstream gene,
p21, has a p53 DNA binding site (DBS) and its activity in
the presence of doxorubicin (p53 transcriptional activator)
was observed as a positive control in normoxia (93) (bar
7). In hypoxic culture conditions, HRE-containing VEGF
promoter showed a significant increase in activity (positive
control; bar 10), which is expected as HIF-1 expression
is observed in hypoxia. This effect was reversed upon ad-
dition of HIF-1α shRNA (negative control; bar 11). Inter-
estingly, the activity of full p53 promoter was significantly
increased under hypoxic conditions but was reversed upon
addition ofHIF-1α shRNA (bars 12 & 13), suggesting tran-
scriptional regulation of p53 by HIF-1. The data compar-
ing p53 promoter activity in HIF-1α shRNA treated nor-
moxic and hypoxic cells (bars 6 & 13), indicates that un-
der normoxia p53 promoter is regulated independent of
HIF-1, but in hypoxic conditions, this transcription factor
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Figure 3. Genetic manipulation of HIF-1 affects p53 expression. (A) Effect ofHIF-1α on p53 expression in knockdown and overexpression experiments
was observed using qRT-PCR in five p53WT and five p53MT cell lines (listed in 3B). Empty vector, HIF-1α-shRNA, non-specific Scr-shRNA, HIF-1α,
or p53-shRNA were transfected in normoxic or hypoxic (1.8% O2) cultured cells for 24 hrs. Hypoxia-induced expression of p53 was abolished by HIF-
1α-shRNA and increased upon exogenous addition of HIF-1α. For each cell line, gene expression was analyzed on three independent replicates (n = 5,
per p53 WT or MT p53 cell lines). Inset: Western blot analysis confirms the effective knockdown of p53 and HIF-1α in PSN1 cells. Two-sided Student’s
t-test was used for analysis; all P values are labeled on the figure. (B) Heat map depicts p53 and HIF-1α gene expression under normoxia and hypoxia for
each WT p53 and MT p53 cancer cell line (quantified in 3A). Results confirm effective knockdown of p53 in by p53-shRNA, knockdown of HIF-1α by
HIF-1α-shRNA, upregulation ofHIF-1α by exogenous addition. Hypoxia-induced expression of WT or MT p53 was dependent onHIF-1α levels. In this
figure, each block represents the values from a gradient scale of low (red), medium (yellow) and high (blue) level of expression (n= 3). (C) Effect ofHIF-1α
knockdown and overexpression on p53 expression was observed by qRT-PCR in WT and HIF-1α KO [MCF-7 (WT p53) and PSN-1 (MT p53)] hypoxic
and normoxic cells. Crispr-generatedHIF-1α null MCF-7 and PSN1 cells show noHIF-1α expression in normoxic and hypoxic cells (2 and 7). In hypoxic
WTHIF-1α MCF-7 and PSN1 cells (panel 3–6), a consistent increase in p53 expression is observed with a dose-dependent increase inHIF-1α expression.
All hypoxic cells were cultured for 24 h in 1.8% O2, n = 3, error bars represent SD. (D) Western blot analysis of whole-cell extracts from HIF-1α-WT
MCF-7 or PSN1 and Crispr-generated HIF-1α-/− MCF-7 and PSN1 cells cultured under normoxia or hypoxia (at 1.8%O2) for 24 h (n = 3 independent
replicates). HIF-1 protein was absent in all cell lines under normoxia and increased in hypoxic HIF-1α-WT cells, but not HIF-1α−/− cells (top panel).
Hypoxia resulted in increased p53 expression inHIF-1α-WT cells, however, in hypoxicHIF-1α−/− cells, depleted of HIF-1  protein, p53 protein does not
increase compared to normoxic HIF-1α−/− cells (middle panel). -actin was used as a loading control. (E) Western blot analysis of HIF-1 and p53 was
performed using whole-cell extracts from HIF-1α WT and HIF-1α−/− MCF-7 cells treated with or without increasing amounts of HIF-1α and cultured
under normoxia or hypoxia (at 1.8%O2) for 24 h (n = 3 independent replicates). HIF-1 and p53 protein increase in hypoxia-treated WT MCF-7 cells
compared to normoxia. In HIF-1α−/− cells, hypoxia does not induce HIF1-, and no significant increase in p53 is observed compared to normoxia (lane
7 versus lane 2). Exogenous addition of HIF-1α to hypoxic HIF-1α−/− cells restores HIF-1 expression and results in robust p53 induction in HIF-1 α
dose-dependent manner (lanes 8–10). -actin was used as the loading control.
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Figure 4. HIF-1 transcriptionally regulates p53. (A) Luciferase assay was used to determine hypoxia-induced and HIF-1-dependent activation of full-
length p53 (10kb) promoter, a known HRE in VEGF promoter was cloned in PGL4 promoter and used as a positive control. Normoxia and hypoxia
p53WTMCF-7 cells were transfected with VEGF-PGL4-HRE or p53 10kb-PGL4 alone or co-transfected with HIF-1α-shRNA under and harvested for
luciferase assay. A known p53 DBS in p21 promoter, p53 p21–5′-DBS-pGL4 was used as a positive control in doxorubicin-treated normoxic MCF-7 cells.
Empty vector or Beta-galactosidase (-Gal) served as normalization controls; error bars represent S.D., n = 3. Two-sided Student’s t-test was used for
analysis; all P values are labeled on the figure. (B) Luciferase assay was used to assess the activity of 5 putative HREs in the p53 promoter, as depicted in
the model. p53WTMCF-7 normoxic and hypoxic cells were transfected with VEGF-PGL4 vector, as a positive control for HIF-1 activity, or each p53-
HRE-PGL4 vectors with or withoutHIF-1α-shRNA. Doxo-treated MCF-7 positive cells transfected with p53 p21-5′-DBS-pGL4 vector serves as positive
control under normoxic conditions. The five p53-HREs sites display hypoxia-inducible luciferase activity that is blocked by shRNA-mediated HIF-1α
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is required for p53 transcription. As described previously
(8,11,63), p53 attains a transcriptionally inactive mutant-
like conformation under hypoxic conditions. Similarly, we
found that under doxorubicin treatment, p53-dependent ac-
tivity at p53-regulated p21 5′DBS in was significantly re-
duced (bar 14); this data is further explained in Figure 5.
Collectively, these results suggested that HIF-1 transcrip-
tionally regulates p53 promoter. To further determine ele-
ments of this HIF-1-mediated p53 regulation, consensus
HIF-1 REs (R/CGTG) in p53 promoter were identified
usingGenomatix tool (99). FiveHREs with 100%matching
with template HRE sequence were found spanning across
p53 promoter, and their locations are depicted in a model
(Figure 4B).
Individual HREs (HRE1–5) were cloned in the pGL4
promoter, and their activity was observed inWT p53MCF-
7 cells. Data showed that all HREs in the p53 promoter re-
gion, along with well-known VEGF promoter HRE were
inactive in normoxic conditions (bars 3–9). Under hypoxia,
the VEGF promoter (positive control) showed a significant
increase in its promoter activity, which was reversed upon
addition of HIF-1α shRNA (Figure 4B, bar 18 & 19). The
newly identified fiveHREs in p53 promoter also showed sig-
nificant HIF-1-dependent increase in their activity, which
was reversed upon HIF-1α silencing (bars 20–29). To fur-
ther identify this phenomenon in WT and MT p53 cell
lines (MCF7 and PSN1) under stricter genetic regulation
(Crispr-assisted HIF-1α null cells), the activity of these five
HREs in p53 promoter was analyzed (Figure 4C). Under
hypoxic conditions, VEGF HRE and five p53 HREs were
active in HIF-1 expressing MCF7 and PSN1 cells (bars
21–26). This activity of the HIF-1-regulated elements in
control (VEGF) and experimental p53 HREs was reversed
in HIF-1α null MCF7 and PSN1 cells. Given that p53
promoter activity under hypoxia appeared to be HIF-1α-
dependent, we next determined whether this regulation was
the result of direct HIF-1 binding to the p53 promoter at
the five predictedHREs.We performed chromatin immuno-
precipitation (ChIP) assay inHIF-1α+/+ (HIF-1α WT) and
HIF-1α−/− (HIF-1α KO) PSN1 cells which showed effec-
tive binding of HIF-1 on all five p53 HREs (Figure 4D,
lane 5). Significant HIF-1 binding to these five p53HREs
was also observed by qChIP from the hypoxic regions of
human kidney, pancreatic, colon, breast, lung and liver tu-
mors (n= 3) (Figure 4E and F). As expected, no occupancy
by HIF-1 occurred on any p53-HRE in normoxic regions
of these tumors; however, a significant enrichment of these
HREs was observed in all human tumor samples. Individ-
ual samples (Figure 4E) or collective binding affinity anal-
ysis (Figure 4F) revealed an exceptionally high affinity of
HIF-1 toward HRE-2, 3 and 4. Since VEGF is a very ac-
tive and high-affinity HRE, it was used as a positive control
to compareHIF-1 affinity towardsHREs in p53 promoter.
Both WT and MT P53 binds to HIF-1
Our results establish that HIF-1 transcriptionally induces
the expression of p53. This finding has important biologi-
cal significance because HIF-1 (pro-tumorigenic) and p53
(tumor suppressor) are known to induce opposite biologi-
cal effects.We and others in the past have demonstrated that
p53 is rendered transcriptionally inactive under physiolog-
ical hypoxia (8,11,63). Despite this inactive conformation,
p53 (both wild-type and mutant forms) which carries an in-
trinsically disordered N-terminus domain (100,88), might
exert its effects via protein-protein interactions. We next in-
vestigated any potential hypoxia-stimulated p53 and HIF-
1 protein interactions in molecular settings. Immunopre-
cipitation (IPP) was performed using anti-p53 ab and anti-
HIF-1 ab in HIF-1α+/+,HIF-1α−/−, p53−/−, and double-
HIF-1α−/−/ p53−/− MCF-7 and PSN1 cells. IPP and devel-
opment with the anti-HIF-1 showed the presence of bands
in WT and p53−/- cells, and HIF-1 bands were missing
in HIF-1α−/− and double-HIF-1−/−/ p53−/− cells (Fig-
ure 5A, top left blot). IPP with anti-HIF-1 and develop-
ment with anti-p53 ab shows the presence of bands in only
WT cells, providing evidence thatHIF-1 binds to bothWT
p53 (MCF-7) and MT p53 (PSN1) forms. Because of the
absence of HIF-1 in lanes 2 and 4, and p53 in lane 3, no
bands were observed.Next, IPP and development with anti-
p53 ab showed bands in WT and HIF-1α KO MCF-7 and
PSN1 cells. To cross-check theHIF-1-p53 interaction, IPP
was performed using anti-p53 ab and developed using anti-
HIF-1 ab, which showed bands in only WT cells, (lane 1,
bottom right blot). We further determined if HIF-1-p53
interaction occurs in human cancers. Nuclear fraction (NF)
from the hypoxic zones of prostate, breast, kidney, lung,
colon, liver, ovarian and pancreatic cancer samples were
collected and, (a) IPP with anti-p53 and development with
anti-HIF-1 and (b) IPP with anti-HIF-1 ab and develop-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
knockdown. Empty vector or Beta-galactosidase (-Gal) served as normalization controls; error bars represent S.D., n= 3. Two-sided Student’s t-test was
used for analysis; all P values are labeled on the figure. (C) Luciferase assay was used to assess the 5 HREs in p53 promoter under normoxia and hypoxia
inHIF-1α-WT/KOMCF-7 and PSN1 cells. All cells were treated as described in (B) and harvested for luciferase assay. In bothHIF1-α-WTMCF-7 (WT
p53) and PSN1 (MT p53) cell lines, hypoxia leads to robust p53 promoter activity at each HRE (lanes 22–26, left and right panel) compared to normoxia.
Hypoxic induction of HRE promoter activity is lost inHIF-1α−/− MCF-7 and PSN1 cells (lanes 31–35, left and right panel), indicating hypoxic induction
of p53 promoter activity is HIF-1-dependent. Empty vector or Beta-galactosidase (-Gal) served as normalization controls; error bars represent S.D., n
= 3. Two-sided Student’s t-test was used for analysis; all P values are labeled on the figure. (D) The ChIP-PCR assay was used to determine if HIF-1 binds
to the five predicted HREs in p53 promoter in hypoxic WT PSN1 and HIF-1α−/− PSN1 cells. Lane 1: chromatin input. Lane 2: No Antibody negative
control. Lane 3: a scrambled primer (Scr Pri) as a control for non-specific DNA PCR amplification. Lane 4: HIF-1α−/− cells as a negative control for
HIF-1 protein binding. Lane 5: binding of HIF-1 protein to each of the 5 HREs is observed, n = 3. (E) Heat map depicts HIF-1 binding to the 5
HREs in p53 promoter measured by ChIP-qPCR in normoxic and hypoxic regions of kidney, pancreatic, colon, breast, lung and liver patient tumors. ChIP
for HIF-1 binding to the VEGF-HRE was included as a positive control to confirm HIF-1 activation and binding activity. Variable HIF-1 binding to
p53-HREs was detected in hypoxic regions, but not normoxic regions, from all cancer types. In this figure, each block represents the values from a gradient
scale of low (red), medium (yellow), and high (blue) level of expression, n = 3 (biological replicates). (F) Box plot summary of ChIP-qPCR enrichment
for each HRE in cancer hypoxic regions as described in (E). Fold enrichment depicts HIF-1 binding to VEGF-HRE or HRE 1–5 in p53 promoter, in the
hypoxic regions relative to HIF-1 binding in the normoxic regions, error bars represent S.D., n = 3.
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Figure 5. Both MT and WT p53 binds to HIF-1. (A) Left panels: Immunoprecipitation (IPP) assay of endogenous HIF-1 from the nuclear fraction of
hypoxia-treated HIF-1α and p53WTMCF7, HIF-1α WT and p53MT PSN1 cells, HIF-1α KOMCF7 and PSN1 cells (Crispr-assisted) and HIF-1α and
p53-double KO MCF7 and PSN1 cells (Crispr-assisted). The top two panels are developed with Anti-HIF-1 Ab. The bottom two panels are developed
with Anti-p53 Ab. Both HIF-1 and p53 bands are observed in WT cells of MCF-7 and PSN1 origin (first lane). No bands are observed in HIF-1α KO
cells as IPP was performed using anti-HIF-1 Ab (lane 2). In p53KO cells bands were observed IPP and development were performed using anti-HIF-1
Ab, and no bands were detected when IPP was performed using anti-HIF-1Ab and development was performed using anti-p53 Ab (lane 3). In lane 4, no
bands were observed as HIF-1α, and p53 double KO cells are used, and IPP is performed using anti-HIF-1 Ab. In the right panel: identical cell lines are
used, but here the IPP is performed using anti-p53 Ab. In lane 1 bands are observed with development with both anti-p53 and anti-HIF-1 Abs. In lane
2 bands are observed in top 2 blots where p53 is IPPed and developed within HIF-1α KO cells, but when blots are developed with anti-HIF-1 Ab, these
bands disappear. In lane 3 and 4, no bands are observed in p53 KO, and HIF-1α and p53 double KO cells as IPP is performed using anti-p53 Ab, n = 3.
(B) Immunoprecipitation (IPP) assay of endogenous p53 and HIF-1 using the nuclear fraction (NF) from hypoxic tissue regions of 8 human cancers. In
the first blot, IPP was performed against anti-p53 Ab and developed for HIF-1 protein; in second blot IPP was performed against anti-HIF-1 Ab and
developed for p53 protein. HIF-1 and p53 were found to co-precipitate with each other in all hypoxic human cancer samples. In the third blot, all IPPs
against HIF-1 show a positive signal for HIF-1  protein, confirming IPP efficiency and antibody accuracy. In the fourth blot, IPP against RNAseH-II,
a protein with no known p53 interaction, and developed against p53 results in no positive p53 signal for all samples, indicating accurate pull-down and
antibody specificity for p53 protein. Positive detection of RNA-Pol II and negative detection of Tubulin were used as a protein loading control and for
confirmation for the purity of nuclear fraction, n= 3. (C) Western blot analysis of p53 expression was performed using normoxic and hypoxic (1.8% O2 for
24 h) p53WT MCF-7-, U2OS- and HepG-2 cells. Hypoxia induces p53 expression in each of the cell lines compared to normoxia. -actin was used as a
loading control, n = 3. (D) In vivo, ELISA was conducted to observe conformation shift recognized by p53 Ab-1620 (p53 WT conformation) and p53 Ab-
240 (p53MT conformation). WT p53MCF-7, UOS2, and HepG2 cells were cultured under normoxia and hypoxia (1.8% O2 for 24 h). Hypoxia resulted in
the loss of p53 Ab-1620 ELISA signal and increased p53 Ab-240 signal, indicating that hypoxia converts p53 to attain a mutant-like conformation, error
bars represent S.D., n= 3. Two-sided Student’s t-test was used for analysis; all P values are labeled on the figure. (E) Luciferase assay was used to observed
p53-mediated activation of its downstream p21 and Bax-minimal promoters. The p53-DBS within the promoter of the p21 and Bax genes, two known
p53 gene targets, were cloned into the pGL4 vector. Normoxic and hypoxic doxorubicin-treated MCF-7 cells were transfected with p53 p21-5′-DBS-pGL4
vector and with p53 Bax-5′-DBS-pGL4 and then harvested for luciferase assay. p53-driven transcriptional activity was lost under hypoxic conditions.
Empty vector or Beta-galactosidase (-Gal) served as normalization controls; error bars represent S.D., n = 3. Two-sided Student’s t-test was used for
analysis; all P values are labeled on the figure.
ment with anti-p53, showed presence of bands, suggesting
HIF-1-p53 interaction in all cancer types. Interaction be-
tween HIF-1 and ARNT/HIF-1 was used as a positive
control in all these cancers. IPP with an antibody against
RNAseH-II, a protein that does not interact with p53, re-
sults in no positive p53 signal, confirming p53 IPP effi-
ciency. The purity of the nuclear fractions from tumors was
checked using western blotting with RNA Pol-II and tubu-
lin (Figure 5B). We further checked the status of the p53
and its molecular conformation and transcriptional activ-
ity in hypoxic cancer cells. Western blot analysis confirmed
that p53 expression was induced in hypoxic MCF-7, U2OS,
and HepG-2 cells (Figure 5C). In vivo ELISA (88) using
p53 wildtype conformation recognizing ab 1620 and mu-
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tant conformation recognizing ab 240 (11) confirmed that
p53 loses its molecular conformation to the attain a mutant
like form under hypoxia (Figure 5D). Also, luciferase assay
using p21-p53 5′ DBS andBax-p53DBS inMCF-7 p53WT
background confirmed that p53 loses its transcriptional ac-
tivity under hypoxia (Figure 5E, compare bars 3 & 4 with
bars 7 & 8).
p53 enhances binding of HIF at HREs
Next, we sought to determine the biological effects of p53-
HIF-1 interactions upon HIF-1 transcriptional activity.
The promoter activity of two well-known targets of HIF-
1, VEGF, and EPO genes, in the presence and absence
of p53, was analyzed by luciferase assay (Figure 6A). In
p53-WT MCF-7 cells, HIF-1 activity on VEGF and EPO
HREs (lanes 3 & 4) was significantly reduced upon addi-
tion of p53 shRNA (lanes 5 & 6). Further, in hypoxicMCF-
7 p53 KO cells, HIF-1 activity at VEGF and EPO HREs
was substantially reduced (lane 9 & 10). Interestingly, the
addition of both WT p53 and MT p53 in p53−/− MCF7
cells led to a significant increase in the transcription of both
VEGF and EPO HREs (lane 11–14) compared to p53-WT
MCF7 cells (Figure 6A). These results suggest since in-
creased p53 led to an increase in HIF-1 transcription fac-
tor activity.Next, we investigatedwhether this was the result
of increased HIF-1 binding to HREs within target genes.
We performed ChIP against HIF-1 on VEGF- and EPO-
HRE in hypoxic WT PSN1 (carrying MT p53 (K132Q))
and PSN1 p53−/− cells. HIF-1 enrichment at both the
VEGF and EPO promoter is significantly reduced in PSN1
p53−/− (Figure 6B, lane 4) compared to wildtype/parental
PSN1 cells (lane 3). Addition of either WT p53 or MT p53
(R175H) to hypoxic p53−/− PSN1 cells resulted in a recov-
ery of HIF-1 binding to VEGF and EPO HREs (lanes
5 & 6). To determine whether p53-regulated HIF-1 re-
cruitment to HIF-1-target genes potentiates HIF-1 tran-
scriptional activity, we performed qChIP on HIF-1 bind-
ing sites within promoter regions of 15 well-known down-
stream genes (86,101,102) from genetically modified tumor
xenografts and human cancer samples. Tumor xenografts of
approximately 4-cm3 volume were generated from p53-WT
MCF-7 and HCT-116 cells, p53−/−-MCF-7 and -HCT-116
cells, and MT p53-transfected p53−/− MCF-7 and HCT-
116 cells. qChIP showed a significant drop in the binding
of HIF-1 to its HREs in hypoxic zones of the p53 null tu-
mors (Figure 6C, lanes 3 & 4, left heat map), when com-
pared with tumor xenografts carrying WT of MT p53 (Fig-
ure 6C). Additionally, we checked the HIF-1-positive hy-
poxic regions in primary biopsies (FFPE samples) collected
from four kidney, three pancreatic and four colon cancers
with low and high p53 expression as shown in Figure 1A
and also in the inset at the bottom of Figure 6C.Hypoxic re-
gions with high and low p53 expression were collected sepa-
rately using FFPE block punches and processed for qChIP.
qChIP using patient cancer samples showed that HIF-1
binding to its HREs significantly decreases in regions with
low p53 expression compared to regions with high p53 ex-
pression, (Figure 6C, compare lane 7–16 with 17–26, mid-
dle heat map). qChIP for 15 HIF-1 downstream genes in
WT p53 (1 each) and MT p53 (1 each) breast, colon, and
pancreatic cancers showed no significant difference in affin-
ity of HIF-1 towards its HREs in the presence of either
WT or MT p53 (lanes 27–32). qPCR was performed to ob-
serve the expression of the same 15 genes in genetically ma-
nipulated tumor xenografts and human tumors. This was
done to determine the outcome of p53-dependent regula-
tion of HIF-1 affinity towards its HREs, and whether the
differences in HRE enrichment translate into differences in
mRNA expression of these genes. Consistent with qChIP
data, qPCR showed a significant reduction in the expres-
sion of 15 HIF-1-regulated genes in p53-null MCF-7 and
HCT-116 tumors (data for both tumor xenografts are com-
bined in the top graph of Figure 6D). Similarly, in hypoxic
regions of kidney, pancreatic and colon cancer patient sam-
ples, mRNA expressions of these 15 genes were lower in re-
gions where expression of p53 was lower (data for all three
tumors are merged in the bottom graph of Figure 6D).
p53-HIF-1 complex interacts with HREs
Collectively, our results show that p53 binds to HIF-1 and
increases HIF-1 transcriptional activity. We next deter-
mined if p53 interacts withHIF-1whileHIF-1 is engaged
at its downstreamHREs, i.e. if a p53-HIF-1 complex binds
to HIF-1 downstreamHREs. We performed ChIP against
p53 andHIF-1 to determine binding atVEGFHRE in hy-
poxic HCT-116 WT cells (which carry WT p53), HCT-116
p53 KO, MCF-7 WT cells (which carry WT p53) and A-
431 WT cells (which carry MT p53) (Figure 7A). We found
that HIF was bound to the VEGF HRE as expected in all
cell lines tested (lane 6), and p53 was bound to the VEGF
HRE inHCT-116,MCF-7, andA-431 cells but not inHCT-
116 p53 KO cells (lane 5). To determine whether the ob-
served p53 binding requiresHIF-1 presence, we conducted
HIF-1 and p53 ChIP-PCR at the VEGF HRE using cells
in which HIF-1α gene is silenced using HIF-1α shRNA in
HCT-116, HCT-116 p53 KO and A-431 cells or CRISPR-
assisted HIF-1α KO cells (Figure 7A).
ChIP inHIF-1α KD and KO cells using anti-HIF-1Ab
onVEGFHRE showed lack of any band, which is expected
because there is no HIF-1 in these cells to bind to VEGF
HRE (lane 7). Interestingly, p53 ChIP using HIF-1α KD
and HIF-1α KO cells reveals that the absence of HIF-1α
abrogates the p53 binding to VEGF HRE (lane 8, com-
pared to lane 5). These results indicate p53 does not bind
to VEGF HRE directly but rather binds to HIF-1 which
interacts with the HRE, and thus a HIF-1-p53 complex
is working in tandem to achieve HIF-1-induced transcrip-
tional activation of HIF downstream genes. To further con-
firm this observation, p53 shRNA was used to knockdown
p53 in HCT-116 WT and A-431 cells and p53 KO MCF-
7 and HCT-116 cells were used to ChIP with anti-p53 ab,
which showed no band in any cell lines, owing to lack of
p53 expression (lane 9). However, ChIP using anti-HIF-1
ab showed binding ofHIF-1 toVEGFHRE in all p53 lack-
ing lines, indicating that HIF-1 binding is not dependent
on p53 presence (lane 10).
This phenomenon was also observed in the hypoxic re-
gions of breast cancer samples carrying MT p53 or WT
p53 (Figure 7A, second panel). ChIP against p53 and HIF
at VEGF HRE in these human cancers showed that both
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Figure 6. WT and MT p53 enhance HIF-1-dependent transcription and binding at HREs of downstream genes. (A) Luciferase activity was observed
to study the impact of both WT and MT p53 on HIF-1-dependent transcription at the minimal promoters of its downstream genes VEGF and EPO.
Hypoxic (1.8% O2, 24 h) p53 WT MCF7 and p53 KO MCF7 cells were co-transfected with VEGF-PGL4 HRE or EPO-PGL4 HRE in the presence of
p53 shRNA, WT p53 or MT p53 and then harvested for luciferase assay. Loss of p53 reduces HIF-1-driven transcription at VEGF and EPO minimal
promoters with HREs. Empty vector or Beta-galactosidase (-Gal) served as normalization controls; error bars represent S.D., n= 3, Two-sided Student’s
t-test was used for analysis; all P values are labeled on the figure. (B) ChIP-PCR assay in hypoxia-treated p53 WT PSN1 and p53 KO PSN1 cells was
performed to observe binding affinity of HIF-1 to the HREs in the VEGF and EPO promoters in presence and absence of WT and MT p53. Lane 1; 2%
input was used, lane 2; no Antibody (Ab) was used as IP control, lane 7; Scrambled primers (scr pri) included as PCR amplification control, lane 8; actin
Ab is used as a negative control. Data shows reduced enrichment of both VEGF and EPO promoters in p53 KO PSN1 cells (lane 4) when compared to
WT PSN1 cells (lane 3). Exogenous addition of WT p53 (lane 5) and MT p53 (lane 6) restores enrichment of HIF-1 at its HREs. (C) Heat map depicts
qChIP assay demonstrating HIF-1 enrichment at the minimal promoters of 15 downstream genes, which are HIF targets with well-defined HREs. DNA
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p53 and HIF-1 were present on the HRE, irrespective of
p53 genetic status. To again study the transcriptional ac-
tivity and DNA binding capacity of p53 in hypoxic tu-
mors and cancers (where it is itself transcriptionally inac-
tive and attains a conformational mutant 240 form), p53-
ChIP was performed onBax p53-DBS, a well-characterized
p53-target gene (93), in normoxic and hypoxic regions of
both WT andMT p53-carrying breast cancers (Figure 7B).
ChIP with anti-p53 ab in normoxic zones of breast can-
cer carrying WT p53 showed a positive interaction (top
panel, lane 5). This interaction was lost in breast can-
cer carrying MT p53 and in hypoxic regions of both WT
and MT p53-carrying breast cancers. The data suggest that
p53 in hypoxic tumors again loses its molecular confor-
mation to interact with DNA and thus cannot be present
on VEGF HREs owing to DNA-protein interaction, but
protein-protein interactions it shares withHIF-1. Amodel
explains how the p53-HIF-1 complex interacts with HRE
(Figure 7C).
WT and MT p53 chaperone HIF-1
The big question remains regarding the biological purpose
of p53-HIF-1 complex binding to HIF downstream target
genes. It is well known that hypoxia-induced stabilization
of HIF-1 supports tumor growth by transcriptionally acti-
vating a myriad of genes that regulate important pro-cancer
biological processes (15). Although p53 is commonly mu-
tated in cancer, nearly 50% of human cancers contain wild-
type p53. Despite the presence of wildtype p53 and its as-
sumed pro-apoptotic activity, HIF-1-induced pro-tumor
activity is generally observed. Recent work has shown the
pro-cancerous role of MT p53 and p53 in the hypoxic con-
text (8,11,63). Thus, it is very unlikely that p53 binding
destabilizes HIF-1, rather it might be co-operating to sta-
bilize HIF-1. This possibility of p53-stabilized HIF-1
transcriptional activity is supported by ourChIP and qPCR
data where the presence of WT and MT p53 both increase
the affinity of HIF-1 towards its HREs, resulting in higher
expression of its downstream genes. We determined if p53
binds toHIF-1 to chaperone and stabilizeHIF-1 binding
to theDNAand thus the synthesis of downstream genes.We
designed an in vivo chaperone assay, as described previously
(63). The molecular mechanism behind the assay is demon-
strated in the model in the inset (Figure 8A). The design
includes co-transfection of a luciferase construct which car-
ries 5 GAL-4 binding domains, followed by a VEGF HRE
where HIF-1 can bind, along with fusion-protein expres-
sion constructs where GAL-4-p53 (MT/WT) proteins can
be expressed in MCF-7 p53 KO cells cultured under nor-
moxia and hypoxic conditions. Because a free p53 molecule
is present in the immediate vicinity of HIF-1 binding to its
HRE, an interaction between p53 andHIF-1 at theVEGF
HRE is forced. If p53 stabilizes and chaperones HIF-1 the
luciferase activity at the VEGF HRE will increase. Data in
bars 1, 2 and 11, 12, show experimental normalizing con-
trols with empty PGL4 backbone and ß-galactosidase in
normoxic and hypoxic MCF-7 p53 KO cells, respectively.
In bars 3–9 (normoxicMCF-7 p53KO cells) and 13–19 (hy-
poxicMCF-7 p53KO cells), theGAL4-binding domain (re-
peated five times)-VEGF HRE-PGL4 vector is transfected.
Under normoxic conditions (bars 3–9) because there is no
HIF-1 expression, the HIF-1-induced luciferase activity
at the VEGF promoter is low. As a positive control in bar
10, p53 activity at a luciferase construct carrying p53 p21
5′DBS is observed in the presence of exogenousWTp53 and
doxorubicin as a p53 activator. Important data is demon-
strated in bars 13–19, where GAL4-binding domain (re-
peated five times)-VEGF HRE-PGL4 vector is transfected
in hypoxic MCF-7 p53 KO cells. A baseline reading is ob-
served in bar 13 because HIF-1 is induced by hypoxia and
drives transcription at the VEGF HRE; thus, a significant
increase compared to bars 3–9 is observed. In bars 14 and
15, along with luciferase vector, a fusion protein expression
vectorwhich codes forGAL4protein fusedwithC-terminus
of WT or MT p53 was transfected in hypoxic MCF-7 p53
KO cells. Data showed a significant increase in HIF-1-
induced transcription at VEGF HRE, suggesting molecu-
lar chaperoning of HIF-1 by both MT and WT p53. To
avoid the possibility of any contribution by GAL4-p53 fu-
sion protein towards this increase in transcription, HIF-1α
shRNA was added in combination with GAL4-MT/WT
p53 protein in bars 16 and 17, which show a significant drop
in HIF-1-induced luciferase activity. Similar results were
observed in hypoxic double p53-KO/HIF-1α KO MCF-7
cells transfected with GAL4-p53 fusion proteins in bars
18 and 19. The data confirm that the transcription at this
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
was harvested from p53WTMCF7, p53WTHCT-116, p53KOMCF7,MT p53MC7 andMT p53HCT116 cell line-derived xenografts grown in the flank
region of the hind leg of nude mice. In addition, patient cancer samples fromKidney (n= 4), pancreatic (n= 3), and colon (n= 3) tumors characterized by
high, or low p53 expression were used. And finally, to observe if WT or MT p53 impacts HIF-1 enrichment at HREs WT p53 and MT p53 breast, colon
and pancreatic patient cancer samples were analyzed. Row 1; 2% input was used in all samples, row 17; no Antibody (Ab) included as IP control, row 18;
Scrambled primers (Scr Pri) included as PCR amplification control and row 19; as non-specific anti-actin Ab as, negative control. In this figure, each block
represents the values from a gradient scale of low (red), medium (yellow) and high (blue) level of expression. HIF-1-enrichment is significantly lower in
hypoxic p53 null tumor xenografts (lane 3, 4), when compared with WT p53 (lanes 1, 2) and MT p53 (lanes 5, 6) tumor xenografts. In the patient samples
hypoxic human tumors regions with high p53 expression, show increased enrichment of HIF-1 on its downstream HREs (lane 7–16), when compared to
regions with low p53 expression (lanes 17–26). Finally, no significant difference in HIF-1 enrichment was observed between WT p53 (lane 27–29) and
MT p53 (lane 30–32) tumor, n = 3. Two-sided Student’s t-test was used for analysis; all P values are labeled on the figure. (D) Top panel: Expression of 15
HIF-regulated genes described in A, were analyzed by qRT-PCR in hypoxic regions p53 WT MCF-7 and HCT-116, p53−/− MCF-7 and HCT-116, and
MT p53 expressing p53−/− MCF-7 and HCT-116 tumor xenografts. Loss of p53 significantly reduced expression of all 15 genes. Data from MCF-7 and
HCT tumors are pooled for analysis, n= 3, error bars represent S.D., n= 3. Two-sided Student’s t-test was used for analysis; all P values are labeled on the
figure. Bottom panel: Expression of these genes is observed in pooled samples from hypoxic regions of four kidney, three pancreatic and four colon tumors
characterized by high and low p53 expression (Inset below the plots). Reduced target gene expression was observed in hypoxic zones of cancers with low
p53 expression compared to hypoxic zones with high p53 expression. Data from tumors with high versus low p53 expression is pooled for analysis, n = 3,
error bars represent S.D., n = 3. Two-sided Student’s t-test was used for analysis; all P values are labeled on the figure.
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Figure 7. BothWT andMT p53 form a transcriptional complex with HIF-1 at HREs. (A) Left panel: ChIP-PCR assay to observe if p53-HIF-1 complex
binds to HREs of HIF downstream genes such as VEGF. In a genetically controlled experiment, WT p53 (HCT-116 and MCF-7), p53 KO MCF-7 and
MT p53 A-431 cells were used. Lane 1; 2% input was used, lane 2; no Antibody (Ab) was used as IP control, lane 3; actin Ab is used as a negative control,
lane 4; Scrambled primers (scr pri) included as PCR amplification control. ChIP with anti-p53 ab for HRE at VEGF minimal promoter gives a band in
WT and MT p53 cells, suggesting that p53 binds to hypoxia response element, lane 5. ChIP with anti-HIF-1 Ab shows bands in all cell types, lane 6. In
lanes 7 and 8,HIF-1α KD and use ofHIF-1α KO cells (MCF-7 origin), results in disappearance for bands for both HIF-1 and p53 Abs, suggesting that
p53 does not bind directly to HREs but is present there because of its binding to HIF-1. In lanes 9 and 10, use of p53 shRNA or p53 KO MCF-7 cells
abolishes all bands for ChIP with anti-p53 Ab, but the bands for ChIP with anti-HIF-1Ab are present, suggesting that p53 is not required for HIF-1 to
bind to its HREs, n = 3. In the second panel: this binding of p53 to HIF-1 response elements is observed in WT and MT hypoxic breast tumors, bands
are observed for both anti-p53 and anti-HIF-1 ChIP, lanes 5 and 6 respectively, suggesting that HIF-1-p53 complex is functional during HIF-driven
transcription in hypoxic human cancers, n= 3. (B) ChIP-PCR assay using Anti-p53 Ab to measure p53 binding to the p53 DBS in the Bax promoter from
normoxic and hypoxic zones of p53WT and p53MT breast cancer patient samples. Lane 1; 2% input was used, lane 2; no Antibody (Ab) was used as IP
control, lane 3; anti-actin Ab was used as a negative control for ChIP, and lane 4; scrambled primers (Scr Pri) included as PCR amplification control. In
lane 5; the data show that p53 binds to Bax p53-DBS only in the presence ofWT p53 in normoxic tumors. In hypoxic tumors of any p53 origin or normoxic
MT p53 tumors, this association is not observed, n= 3. (C) A model shows the mechanism where WT/MT p53 binds to HIF-1 and not to HREs directly.
GAL4-binding domain (repeated five times)-VEGF HRE-
PGL4 vector is driven by HIF-1 and presence of MT/WT
p53 in its immediate vicinity stabilizesHIF-1 and increases
its transcriptional activity in this molecular chaperone as-
say. We next asked whether the transcriptional effects of
the p53-HIF-1 complex were the result of altered HIF-
1 protein stability. We performed cycloheximide chase to
determine the effects of p53 on HIF-1 protein stability
and found that exogenous addition of WT or MT p53 to
MCF-7 p53-KO cells (Figure 8B, lanes 4–9) under hypoxia
enhanced HIF-1 stability compared to controls (lanes 1–
3). These results indicate that the formation of p53-HIF-1
complex protects HIF-1 against protein degradation. The
statistical analysis and quantification of the cycloheximide
chase experiment is presented (Figure 8C).
Chaperoning of HIF-1 by WT and MT p53 increases HIF
transcriptional ability
Themolecular chaperone assay establishes that p53 can sta-
bilize and promote HIF-1-induced transcription in cellu-
lar conditions, we observed if this phenomenon holds true
for in vitro transcription (Figure 9A). An in vitro transcrip-
tion cassette was designed as shown previously (85,91,92),
six VEGF HREs were repeated to ensure robust HIF bind-
ing, followed by AdML core promoter followed by a start
codon of a G-less cassette followed by a Poly-A tail. The
RNA-Pol II machinery and required transcription factor
HIF and molecular chaperone p53 were obtained from nu-
clear extracts of MCF-7 HIF-1α KO, p53 KO, and dou-
ble HIF-1α p53 KO cells, and the readout of the assay was
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Figure 8. Hypoxic WT & MT p53 chaperones HIF-1 at chromatin. (A) In vivo Chaperone Assay to measure the ability of WT or MT p53 to chaperone
HIF-1. The output read of this chaperone assay is the increase HIF-1-driven transcription at its downstream VEGF HRE. p53−/− MCF7 or p53
and HIF-1α double KO MCF-7 cells were co-transfected with [GAL4-BD]5-VEGF-HRE luciferase construct together with GAL4, WT p53-GAL4, MT
p53-GAL4 alone or in combination with HIF-1α shRNA. In the left panel, this HIF-driven construct shows no activity in normoxia-cultured cells (lane-
3–9), p53-driven p21 luciferase vector in doxorubicin-treated cells, is used as a positive control in normoxia (lane 10). Under hypoxic conditions, a baseline
activity of the HIF-1-drivenVEGF promoter is observed (lane 13). Interestingly presence ofWT p53 (lane 14) orMT p53 (lane 15) as chaperone increases
HIF-1-driven transcription; this effect is lost upon addition of HIF-1α shRNA or in HIF-1α KO cells (lane16–19). Empty vector or Beta-galactosidase
(-Gal) served as normalization controls; error bars represent S.D., n = 3. Two-sided Student’s t-test was used for analysis; all P values are labeled on the
figure. (B) Western blot analysis of cycloheximide chase to study the effects of p53 expression on HIF-1 protein stability. p53KOMCF-7 cells and p53KO
MCF-7 cells transfected with WT p53 or MT p53 were cultured under hypoxia for 24 h and treated with cycloheximide (100 g/ml) for indicated times.
HIF-1 protein is degraded within 6 h in p53 KO cells (lane 3), but both WT and MT p53 protect HIF-1  against protein degradation (lanes 6 and 9).
(C) Statistical analysis and quantification of the HIF-1 protein expression during the cycloheximide chase experiment shown in Figure 8B is presented.
Error bars represent S.D., n = 3. Two-sided Student’s t-test was used for analysis; all P values are labeled on the figure.
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Figure 9. Chaperoning ofHIF-1 byWT&MTp53 promotesHIF-1 transcriptional activity. (A) In vitro transcription assay was performed using a cassette
designed with six VEGF HRE repeats, followed by AdML core promoter, start codon of a G-less cassette and Poly-A tail. The RNA-Poll machinery and
required transcription factor HIF-1 and molecular chaperone p53 were obtained from nuclear extracts of MCF-7HIF-1α KO, p53KO, and doubleHIF-
1α p53KO cells, and the readout of the assay was obtained by qPCR and by QIAXEL. In lane 1 no DNA template is added (negative control). No signal
is observed where HIF-1 is lacking, lane 2–5. A signal is observed in from nuclear extract of MCF-7HIF-1α and p53 double KO exogenously transfected
with HIF-1α (lane 6), which is further amplified by rescuing WT or MT p53 expression (lanes 7–9). Exogenous addition of p53 N-terminus (A.A. 1–125)
also rescues HIF-1-driven transcription (lane 10). No signal is observed from normoxic cells because they lack HIF-1 expression (lane 11–12). Error
bars represent S.D., n= 3. Two-sided Student’s t-test was used for analysis; all P values are labeled on the figure. (B) Effects of chaperone assay and in vitro
transcription are observed in cellular conditions. Luciferase assay was performed on normoxic and hypoxic MCF-7 cells of different genetic backgrounds
transfected with PGL4 luciferase vector with a VEGF HRE. Under hypoxia, cells carrying WT HIF-1α and WT p53 show a significant increase in VEGF
HRE activity that is inhibited by loss of HIF-1α or p53 and augmented by overexpression of WT or MT p53. Error bars represent S.D., n = 3. Two-sided
Student’s t-test was used for analysis; all P values are labeled on the figure. (C) The effects ofHIF-1α and p53 genetic manipulation were tested on a panel
of 5 HIF-1 downstream genes, EPO, GPI, SERPINE1, VEGFA, and NDRG1. Genetically manipulated normoxic or hypoxic MCF-7 cells were used
for qRT-PCR analysis. Heat map depicts the gene expression of HIF-1 target genes. HIF-1-regulated genes are poorly expressed under normoxia and
highly induced by hypoxia plus overexpression of WT or MT p53 inHIF+/+; p53−/− cells. p53-induced upregulation of HIF-1 target genes is diminished
by concurrent HIF-1 deficiency. In this figure, each block represents the values from a gradient scale of low (red), medium (yellow) and high (blue) level
of expression, n = 3. Two-sided Student’s t-test was used for analysis; all P values are labeled on the figure.
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obtained by qPCR and by QIAXEL. A series of controls
were run. In lane 1, bar 1 the in vitro transcription tem-
plate was not added, and thus no signal was observed. In
lane 2, bar 2 the template was added, but the MCF-7 HIF-
1α KO nuclear extract was used, which again resulted in no
signal. In lane 3, bar 3 nuclear extract fromMCF-7HIF-1α
and p53 double KO was used. In lane 4, bar 4 and lane 5,
bar 5 nuclear extracts fromMCF-7HIF-1α KO cells trans-
fected with WT p53 and MT p53 were used, because HIF-
1α is lacking in all these nuclear extracts no signal was ob-
served. In lane 6, bar 6 nuclear extract fromMCF-7HIF-1α
and p53 double KO exogenously transfected with HIF-1α
was used, because HIF-1α was present in this extract a sig-
nal was observed, this also served as a positive control for
the experiment. Next, the nuclear extract of MCF-7 HIF-
1α KO cells which carry WT p53, transfected with HIF-1α
was used, which resulted in a significant increase in HIF-1
transcriptional activity (lane 7, bar 7). To observe this p53-
induced increase in HIF-1 transcriptional activity, nuclear
extract fromMCF-7HIF-1α KO cells transfected with WT
p53 and MT p53 was used in lane 8, bar 8 and lane 9, bar
9 respectively. A significant increase in the HIF-1-induced
transcription was observed in the presence of both MT and
WT p53. In lane 10, bar 10 the nuclear extract fromMCF-7
p53 KO cells transfected with HIF-1α and p53 NTD (N-
terminus domain, amino acid 1–125) was used as a con-
trol of p53 chaperoning activity, based on purported chap-
eroning abilities of p53 NTD (63). In lane 11, bar 11 and
lane 12, bar 12 nuclear extracts from normoxic MCF-7WT
cells and MCF-7 p53 KO cells were used, which resulted in
no signal, suggesting that p53 does not influence this tran-
scription in the absence of HIF-1. Since the in vitro tran-
scription data support the findings of the molecular chaper-
one assay, next we determined to see the same this identical
in vitro transcription panel in cellular conditions using lu-
ciferase assay (Figure 9B). Normoxic and hypoxic MCF-7
cells of different genetic backgrounds were transfected with
PGL4 luciferase vector with aVEGFHRE. In the left panel
bars 1–10, because of lack of HIF-1 in normoxic cells lu-
ciferase activity at VEGF HRE is low, in bar 11, a positive
control is usedwhereMCF-7 cells were transfectedwith p53
p21 5′DBS in the presence of doxorubicin. In hypoxic cells,
bars 12 and 13 served as normalization controls with empty
vector and ß-Galactosidase. In bar 14, MCF-7HIF-1α KO
cells show a lack of activity, whereas, in bar 15, WTMCF-7
cells carrying HIF-1α and WT p53 show a significant in-
crease in VEGF HRE activity. This activity is reversed in
MCF-7HIF-1α and p53 double KO cells (bar 16), and dou-
ble KO cells in the presence ofWT p53 (bar 17) andMT p53
(bar 18). In bar 19, MCF-7 p53 KO cells which carry HIF-
1α show an increase in activity, but lower than WTMCF-7
cells which carryWT p53 (bar 15). Addition ofWT andMT
p53 in MCF-7 p53KO cells, bars 20 and 21, respectively, re-
sults in a significant increase in HIF-1-induced activity at
VEGF HRE. Bar 22 shows reduced transcriptional activ-
ity of p53 on p21 5′DBS in hypoxic cells when compared to
bar 11. Next, we analyzed the impact of this panel on HIF-
1-induced expression of its five downstream genes, EPO,
GPI, SERPINE1, VEGFA and NDRG1 with qPCR in ge-
netically manipulated hypoxic and normoxic MCF-7 cells
(Figure 9C). In lane 1–8, because the cells were cultured in
normoxic conditions, expression of most of these HIF-1-
regulated genes is poor. In lane 9, 11, 12 and 13 hypoxic
MCF-7 HIF-1α KO or HIF-1α and p53 double KO cells
show poor expression of these genes, most likely because of
lack of HIF-1α. In WT MCF-7 cells which carry HIF-1α
and WT p53 expression of these genes is significantly in-
creased (lane 10). However, in p53KOMCF-7 cells expres-
sion of these genes is significantly reduced (lane 14), this
reduction is reversed upon exogenous addition of WT p53
(lane 15) andMT p53 (lane 16). All the data frommolecular
chaperone assay, in vitro transcription, in vivo luciferase as-
say and qPCR assay in a consistent panel of normoxic and
hypoxic MCF-7, MCF-7 HIF-1α KO, MCF-7 p53 KO and
MCF-7 HIF-1α and p53 double KO cells, establish the fact
that p53 chaperones and stabilizes HIF-1 while it binds to
HREs of its downstream genes, resulting in more efficient
transcription and thus advanced pro-tumor activity.
DISCUSSION
Here, we have discovered a novel feedback loop operational
between p53 and HIF-1. With the help of non-invasive O2
measurements in human tumor xenografts using electron
paramagnetic resonance, we made considerable effort to
identify and simulate physiologically relevant oxygen con-
ditions (∼1.8% O2). This unique feedback loop is observed
upon hypoxia-induced activation of HIF-1, which binds
to its response elements on the p53 promoter and results
in upregulation of both WT and MT p53 proteins depend-
ing on p53 genetic status. The p53 transcriptional activity
under hypoxic conditions is compromised, and both ge-
netic WT and MT p53 attains a conformational mutant
phenotype. This upregulated p53 protein binds and chaper-
onesHIF-1, which results in increased binding and affinity
of HIF towards the response elements (REs) of its down-
stream genes. Thus, p53-assisted HIF-1 chaperoning in-
creases efficiency of HIF to function as a pro-cancer tran-
scription factor. HIF-1-p53 (MT/WT) complex is found
binding at specific HRE ofHIF downstream genes and sup-
ports the fact that hypoxic tumors where p53 and HIF-1
both are upregulated are associated with a worse prognosis.
A model in Figure 10 summarizes these findings.
HIF-induced p53 upregulation has been previously re-
ported in both WT p53 (13), and MT p53 (60) cells and a
positive correlation between the expression of p53 andHIF-
1 was observed (59,103). However, this study presents an
in-depth analysis in hypoxic regions of solid tumors to es-
tablish the relationship between p53 and HIF-1 mRNA
and protein expression in a variety of tumors. Our results
with ChIP and luciferase assay demonstrate that p53 pro-
moter is under HIF regulation, which transcriptionally in-
duces the synthesis of both WT and MT p53. Consensus
hypoxia response elements R/CGTG within p53 promoter
were identified to be enriched with HIF-1, providing con-
crete answers to the question of whether HIF-1 induces
expression of p53 and it upregulates MT or WT p53, as
was observed previously (56,57,104–106). We and others
have consistently found that p53 is transcriptionally com-
promised in hypoxic cells, and some groups found that it
can only function as a trans-repressor (63,64,107). Here and
in our previous studies, we have shown that both WT and
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Figure 10. Model depiction: Positive feedback loop between HIF-1 and p53 drives HIF-1 downstream signaling. Hypoxia-stimulated HIF-1 binds to
HREs within p53 promoter and increases p53 transcription resulting in p53 protein accumulation. Under hypoxia, p53 may obtain a MT conformation.
BothMT andWT p53 bind to HIF-1 protects HIF-1  against protein degradation and chaperones HIF-1 toward the response elements of target genes,
increasing transcriptional activity. Ultimately, p53-chaperoning of HIF-1  under hypoxia exacerbates HIF-1  signaling, fueling the pro-tumorigenic
properties of HIF-1.
MT p53 genetic mutants under hypoxic conditions adopt a
transcriptionally inactive mutant-like protein conformation
recognized by pAB 240 instead of pAB 1620 (11).
Binding between WT/MT p53 and HIF-1 under in
vitro and in vivo conditions has been shown previously
(61,62,108), but the question still remained whether WT
or MT p53 or both can bind to HIF-1 in hypoxic cells.
p53 is intrinsically disordered at its N- and C-terminus
and stable in its core domain and is known to inter-
act with many proteins, such as CBP/p300, CSN5/Jab1,
Mdm2, RPA, TFIID, 14–3-3, GSK3, hGcn5, PARP-1,
S100B(), TAF, TAF1, TRRAP, TFIIH, along with HIF-
1 and many other proteins, clearly illustrating exceptional
binding promiscuity of p53 (109). Thus p53-HIF-1 inter-
action in its upregulated levels is easy to understand. We
further show evidence of p53-HIF-1 binding in Crispr-
assisted p53 null, HIF-1α null, and p53+HIF-1α nulls cells
with WT p53 carrying MCF-7 cells and MT p53 carrying
PSN1 cells. A recent study demonstrated the ability of HIF-
1 to bind to MT p53 proteins (such as p53 R273H and
p53 R246I) with compromised p53-DNA interactions (60),
whereas our results indicate that this interaction is univer-
sal and occurs with WT p53 and a large variety of p53 mu-
tants. We further observed that the HIF-1-p53 complex
together binds to theDNA response elements ofHIF down-
stream genes. At HIF-response elements, p53 does not di-
rectly interact with DNA but rather binds to and chaper-
ones HIF-1. A similar observation was also recently made
Nucleic Acids Research, 2019, Vol. 47, No. 19 10231
(60), with the exception that not only MT p53 but also WT
p53 demonstrate similar nature of interactions with HIF-
1.
In this study for the first time, we demonstrate that both
WT and MT p53 can serve as a molecular chaperone and
stabilize HIF-1. We have used cutting-edge molecular de-
sign for developing an in vivo chaperone assay and in vitro
transcription assay to establish that both MT and WT p53
chaperones and stabilizes HIF-1 and promotes HIF-1-
induced transcription at hypoxia DNA response elements.
This results in an increased efficiency of HIF-1 to upregu-
late expression of its downstream genes involved in regula-
tion of important biological processes such as, but not lim-
ited to, glucose uptake (20,21), metabolism (22–24), angio-
genesis (25,26), erythropoiesis (27), cell proliferation (28),
differentiation (29), and apoptosis (30). Recently, it was sug-
gested that HIF-1 forms a protein complex exclusively
with MT p53, and this complex is also found at the chro-
matin (60). Our ChIP results on HIF-regulated REs sug-
gest that bothWT andMTp53 form complex withHIF-1,
and this complex directly interact with the DNA elements.
It is important to note that p53 does not directly bind to
HREs. Recent reports suggest that MT p53 assists HIF-1
in activating hypoxia-regulated genes because it recruits an
SWI/SNF chromatin remodeling complex and it is the pres-
ence of SWI/SNF which facilitates activation of a specific
subset of genes such as the ECM components type VIIa1
collagen and laminin-2 (60). Our data identify that rela-
tion between bothWT/MT p53 and HIF-1 is more direct,
where the bothWT/MTp53 can chaperoneHIF-1 directly
while in a complex at the chromatin, this chaperoning stabi-
lizes HIF-1-HRE interactions and globally improves syn-
thesis of HIF-downstream genes involved in cell survival,
angiogenesis, and regulation of metabolism, etc., and are
not limited to ECM components.
Here, we have presented definitive evidence of a unique
physiological situation under which WT p53 can function
as a tumor promoter by its chaperone activity towardsHIF-
1, previously, the pro-cancerous role of MT p53 was dis-
covered (109–111). This finding demonstrates the dual role
of p53 has great implications and showcases the complexity
of p53 signaling given that p53 may function as a tumor-
suppressor in normoxic regions (a transcriptional mecha-
nism) and as a tumor-promoter (chaperone for HIF-1) in
hypoxic regions of the same tumor.
The finding that both WT and MT p53 bind and
chaperone HIF-1 is very important because no hypoxia-
associated disease model other than cancer is known to har-
bor p53 mutations and carry WT p53 genotype, thus WT
p53-HIF-1 specific interactions can drive similar molec-
ular effects in other hypoxia-associated diseases. Therefore,
this finding also has implications beyond cancer in other hy-
poxic disease models such as chronic inflammatory bowel
disease, rheumatoid arthritis, and ischemia/reperfusion in-
jury, cystic fibrosis, chronic bronchitis, stroke, psoriasis, di-
abetic vasculopathy, and epilepsy. In human disease patho-
physiology, alteration of HIF-1 activity prominently af-
fects vascularization in ischemia (i.e., myocardial, cerebral,
retinal), hypertension, and tumor progression. Chronic
overexpression of HIF-1 is witnessed in patients with Von
Hippel-Lindau (VHL) syndrome, a genetic disease affect-
ing blood vessel growth that is characterized by increased
tumor formation (112). VHL tumor suppressor is an E3
ubiquitin ligase that targets alpha subunits of HIFs for
proteasomal degradation under normoxic conditions (113).
Loss of VHL creates a pseudo hypoxic environment lead-
ing to HIF stabilization (112). VHL-deficient carcinoma
cells are shown to overproduce direct HIF targets, VEGF,
GLUT1, PDGF-B, andCXCR4 (112,114,115). On the other
end of the spectrum,HIF-1 abrogation produces opposing
effects. Complete deficiency of HIF-1 causes embryonic
lethality in Hif1a−/− mice owing to cardiac and vascular
malformations (116). Chronic hypoxia treatment of wild-
type mice leads to the development of polycythemia, right
ventricular hypertrophy, pulmonary hypertension, and pul-
monary vascular remodeling, all of which are delayed by
partial HIF-1 deficiency in HIF1a+/− mice (117). Con-
ditional and tissue-specific manipulation of VHL/HIF-1
pathway reveals pivotal roles in osteogenesis (118), pancre-
atic beta-cell insulin secretion (119), myeloid cell-mediated
inflammation (120), and development of the sympathetic
nervous system (121). A significant threat to cardiovascu-
lar health is cardiac ischemia and subsequent hypertrophy.
In a mouse model of pressure overload, HIF-1 activation
initially promoted vascular growth in the heart by induc-
ing angiogenic factors (122). However, sustained pressure
overload led to p53 accumulation and HIF-1 inhibition,
causing a transition from cardiac hypertrophy toward heart
failure (122). This newly discovered HIF-1 and p53 rela-
tionship in light of these disease models is critical in under-
standing and explaining peculiar clinical findings and ob-
servations.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We thank Dr. Harikrishna Nakshatri for his support and
AenyaGogna for her help.We acknowledgeMTTplatform,
clinical histopathology platform and rodent platform at the
Champalimaud Foundation.
FUNDING
Swiss Cancer League [LB692]; Seeds of Science, Champal-
imaud Foundation; Winthrop P Rockefeller Cancer Insti-
tute; CreightonUniversity startup funds (toR.G.). Funding
for open access charge: ChamplaimaudFoundation Startup
Grant.
Conflict of interest statement.None declared.
REFERENCES
1. Simon,M.C. and Keith,B. (2008) The role of oxygen availability in
embryonic development and stem cell function. Nat. Rev. Mol. Cell
Biol., 9, 285–296.
2. Giaccia,A.J., Simon,M.C. and Johnson,R. (2004) The biology of
hypoxia: the role of oxygen sensing in development, normal
function, and disease. Genes Dev., 18, 2183–2194.
3. Semenza,G.L. (2001) Hypoxia-inducible factor 1: control of oxygen
homeostasis in health and disease. Pediatr. Res., 49, 614–617.
10232 Nucleic Acids Research, 2019, Vol. 47, No. 19
4. Hong,W.X., Hu,M.S., Esquivel,M., Liang,G.Y., Rennert,R.C.,
McArdle,A., Paik,K.J., Duscher,D., Gurtner,G.C., Lorenz,H.P.
et al. (2014) The role of Hypoxia-Inducible factor in wound healing.
Adv. Wound Care (New Rochelle), 3, 390–399.
5. Ruthenborg,R.J., Ban,J.J., Wazir,A., Takeda,N. and Kim,J.W. (2014)
Regulation of wound healing and fibrosis by hypoxia and
hypoxia-inducible factor-1.Mol. Cells, 37, 637–643.
6. Bell,S.L. and Eveson,D.J. (2011) An unusual cause of stroke and
hypoxia. BMJ, 342, c7200.
7. Ferdinand,P. and Roffe,C. (2016) Hypoxia after stroke: a review of
experimental and clinical evidence. Exp. Transl. Stroke Med., 8, 9.
8. Achison,M. and Hupp,T.R. (2003) Hypoxia attenuates the p53
response to cellular damage. Oncogene, 22, 3431–3440.
9. Deben,C., Deschoolmeester,V., De Waele,J., Jacobs,J., Van den
Bossche,J., Wouters,A., Peeters,M., Rolfo,C., Smits,E., Lardon,F.
et al. (2018) Hypoxia-Induced cisplatin resistance in Non-Small cell
lung cancer cells is mediated by HIF-1 alpha and Mutant p53 and
can be overcome by induction of oxidative stress. Cancers, 10, E126.
10. Goda,N., Ryan,H.E., Khadivi,B., McNulty,W., Rickert,R.C. and
Johnson,R.S. (2003) Hypoxia-inducible factor 1 alpha is essential
for cell cycle arrest during hypoxia.Mol. Cell Biol., 23, 359–369.
11. Gogna,R., Madan,E., Kuppusamy,P. and Pati,U. (2012)
Re-oxygenation causes hypoxic tumor regression through
restoration of p53 wild-type conformation and post-translational
modifications. Cell Death Dis., 3, e286.
12. Graeber,T.G., Osmanian,C., Jacks,T., Housman,D.E., Koch,C.J.,
Lowe,S.W. and Giaccia,A.J. (1996) Hypoxia-mediated selection of
cells with diminished apoptotic potential in solid tumours. Nature,
379, 88–91.
13. Hammond,E.M., Denko,N.C., Dorie,M.J., Abraham,R.T. and
Giaccia,A.J. (2002) Hypoxia links ATR and p53 through replication
arrest.Mol. Cell Biol., 22, 1834–1843.
14. Hockel,M., Schlenger,K., Hockel,S. and Vaupel,P. (1999) Hypoxic
cervical cancers with low apoptotic index are highly aggressive.
Cancer Res., 59, 4525–4528.
15. LaGory,E.L. and Giaccia,A.J. (2016) The ever-expanding role of
HIF in tumour and stromal biology. Nat. Cell Biol., 18, 356–365.
16. Oh,S.Y., Kwon,H.C., Kim,S.H., Jang,J.S., Kim,M.C., Kim,K.H.,
Han,J.Y., Kim,C.O., Kim,S.J., Jeong,J.S. et al. (2008)
Clinicopathologic significance of HIF-1alpha, p53, and VEGF
expression and preoperative serum VEGF level in gastric cancer.
BMC Cancer, 8, 123.
17. Singh,D., Arora,R., Kaur,P., Singh,B., Mannan,R. and Arora,S.
(2017) Overexpression of hypoxia-inducible factor and metabolic
pathways: possible targets of cancer. Cell Biosci., 7, 62–70.
18. Welford,S.M. and Giaccia,A.J. (2011) Hypoxia and Senescence: The
impact of oxygenation on tumor suppression.Mol Cancer Res., 9,
538–544.
19. Yamamoto,Y., Ibusuki,M., Okumura,Y., Kawasoe,T., Kai,K.,
Iyama,K. and Iwase,H. (2008) Hypoxia-inducible factor 1 alpha is
closely linked to an aggressive phenotype in breast cancer. Breast
Cancer Res. Trans., 110, 465–475.
20. Denko,N.C. (2008) Hypoxia, HIF1 and glucose metabolism in the
solid tumour. Nat. Rev. Cancer, 8, 705–713.
21. Eales,K.L., Hollinshead,K.E. and Tennant,D.A. (2016) Hypoxia
and metabolic adaptation of cancer cells. Oncogenesis, 5, e190.
22. Brahimi-Horn,M.C., Chiche,J. and Pouyssegur,J. (2007) Hypoxia
signalling controls metabolic demand. Curr. Opin. Cell Biol., 19,
223–229.
23. Rajendran,J.G., Mankoff,D.A., O’Sullivan,F., Peterson,L.M.,
Schwartz,D.L., Conrad,E.U., Spence,A.M., Muzi,M., Farwell,D.G.
and Krohn,K.A. (2004) Hypoxia and glucose metabolism in
malignant tumors: evaluation by [18F]fluoromisonidazole and
[18F]fluorodeoxyglucose positron emission tomography imaging.
Clin. Cancer Res., 10, 2245–2252.
24. Kim,J.W., Tchernyshyov,I., Semenza,G.L. and Dang,C.V. (2006)
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a
metabolic switch required for cellular adaptation to hypoxia. Cell
Metab, 3, 177–185.
25. Ozawa,K., Kondo,T., Hori,O., Kitao,Y., Stern,D.M.,
Eisenmenger,W., Ogawa,S. and Ohshima,T. (2001) Expression of the
oxygen-regulated protein ORP150 accelerates wound healing by
modulating intracellular VEGF transport. J. Clin. Invest., 108,
41–50.
26. Liao,D. and Johnson,R.S. (2007) Hypoxia: a key regulator of
angiogenesis in cancer. Cancer Metastasis Rev., 26, 281–290.
27. Haase,V.H. (2010) Hypoxic regulation of erythropoiesis and iron
metabolism. Am. J. Physiol. Renal. Physiol., 299, F1–F13.
28. Hubbi,M.E. and Semenza,G.L. (2015) Regulation of cell
proliferation by hypoxia-inducible factors. Am. J. Physiol. Cell
Physiol., 309, C775–C782.
29. Zhu,L.L., Wu,L.Y., Yew,D.T. and Fan,M. (2005) Effects of hypoxia
on the proliferation and differentiation of NSCs.Mol. Neurobiol.,
31, 231–242.
30. Semenza,G.L. (2012) Hypoxia-inducible factors in physiology and
medicine. Cell, 148, 399–408.
31. Chan,M.C., Holt-Martyn,J.P., Schofield,C.J. and Ratcliffe,P.J. (2016)
Pharmacological targeting of the HIF hydroxylases–A new field in
medicine development.Mol. Aspects Med., 47-48, 54–75.
32. Kung,A.L., Zabludoff,S.D., France,D.S., Freedman,S.J.,
Tanner,E.A., Vieira,A., Cornell-Kennon,S., Lee,J., Wang,B.,
Wang,J. et al. (2004) Small molecule blockade of transcriptional
coactivation of the hypoxia-inducible factor pathway. Cancer Cell,
6, 33–43.
33. Semenza,G.L. (2012) Hypoxia-inducible factors: mediators of
cancer progression and targets for cancer therapy. Trends
Pharmacol. Sci., 33, 207–214.
34. Jaakkola,P., Mole,D.R., Tian,Y.M., Wilson,M.I., Gielbert,J.,
Gaskell,S.J., von Kriegsheim,A., Hebestreit,H.F., Mukherji,M.,
Schofield,C.J. et al. (2001) Targeting of HIF-alpha to the von
Hippel-Lindau ubiquitylation complex by O2-regulated prolyl
hydroxylation. Science, 292, 468–472.
35. Semenza,G.L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev.
Cancer, 3, 721–732.
36. Jiang,B.H., Semenza,G.L., Bauer,C. and Marti,H.H. (1996)
Hypoxia-inducible factor 1 levels vary exponentially over a
physiologically relevant range of O2 tension. Am. J. Physiol., 271,
C1172–C1180.
37. Graham,A.M. and Presnell,J.S. (2017) Hypoxia Inducible Factor
(HIF) transcription factor family expansion, diversification,
divergence and selection in eukaryotes. PLoS One, 12, e0179545.
38. Semenza,G.L. and Wang,G.L. (1992) A nuclear factor induced by
hypoxia via de novo protein synthesis binds to the human
erythropoietin gene enhancer at a site required for transcriptional
activation.Mol. Cell Biol., 12, 5447–5454.
39. Gu,Y.Z., Moran,S.M., Hogenesch,J.B., Wartman,L. and
Bradfield,C.A. (1998) Molecular characterization and chromosomal
localization of a third alpha-class hypoxia inducible factor subunit,
HIF3alpha. Gene Expr., 7, 205–213.
40. Koh,M.Y., Lemos,R. Jr., Liu,X. and Powis,G. (2011) The
hypoxia-associated factor switches cells from HIF-1alpha- to
HIF-2alpha-dependent signaling promoting stem cell characteristics,
aggressive tumor growth and invasion. Cancer Res., 71, 4015–4027.
41. Obacz,J., Pastorekova,S., Vojtesek,B. and Hrstka,R. (2013)
Cross-talk between HIF and p53 as mediators of molecular
responses to physiological and genotoxic stresses.Mol. Cancer, 12,
93–102.
42. Marin-Hernandez,A., Gallardo-Perez,J.C., Ralph,S.J.,
Rodriguez-Enriquez,S. and Moreno-Sanchez,R. (2009) HIF-1alpha
modulates energy metabolism in cancer cells by inducing
over-expression of specific glycolytic isoforms.Mini Rev. Med.
Chem., 9, 1084–1101.
43. Bartoszewska,S., Kochan,K., Piotrowski,A., Kamysz,W.,
Ochocka,R.J., Collawn,J.F. and Bartoszewski,R. (2015) The
hypoxia-inducible miR-429 regulates hypoxia-inducible
factor-1alpha expression in human endothelial cells through a
negative feedback loop. FASEB J., 29, 1467–1479.
44. Maynard,M.A., Evans,A.J., Shi,W., Kim,W.Y., Liu,F.F. and Ohh,M.
(2007) Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal
cell carcinoma progression. Cell Cycle, 6, 2810–2816.
45. Makino,Y., Cao,R., Svensson,K., Bertilsson,G., Asman,M.,
Tanaka,H., Cao,Y., Berkenstam,A. and Poellinger,L. (2001)
Inhibitory PAS domain protein is a negative regulator of
hypoxia-inducible gene expression. Nature, 414, 550–554.
46. Vousden,K.H. and Lu,X. (2002) Live or let die: the cell’s response to
p53. Nat. Rev. Cancer, 2, 594–604.
Nucleic Acids Research, 2019, Vol. 47, No. 19 10233
47. Yue,X., Zhao,Y., Xu,Y., Zheng,M., Feng,Z. and Hu,W. (2017)
Mutant p53 in Cancer: Accumulation, Gain-of-Function, and
Therapy. J. Mol. Biol., 429, 1595–1606.
48. Oren,M. and Rotter,V. (2010) Mutant p53 gain-of-function in
cancer. Cold Spring Harb. Perspect. Biol., 2, a001107.
49. Milner,J. and Watson,J.V. (1990) Addition of fresh medium induces
cell cycle and conformation changes in p53, a tumour suppressor
protein. Oncogene, 5, 1683–1690.
50. Zhang,W., Hu,G., Estey,E., Hester,J. and Deisseroth,A. (1992)
Altered conformation of the p53 protein in myeloid leukemia cells
and mitogen-stimulated normal blood cells.Oncogene, 7, 1645–1647.
51. Bartek,J., Iggo,R., Gannon,J. and Lane,D.P. (1990) Genetic and
immunochemical analysis of mutant p53 in human breast cancer cell
lines. Oncogene, 5, 893–899.
52. Xu,J., Reumers,J., Couceiro,J.R., De Smet,F., Gallardo,R.,
Rudyak,S., Cornelis,A., Rozenski,J., Zwolinska,A., Marine,J.C.
et al. (2011) Gain of function of mutant p53 by coaggregation with
multiple tumor suppressors. Nat. Chem. Biol., 7, 285–295.
53. Zhang,Y., Coillie,S.V., Fang,J.Y. and Xu,J. (2016) Gain of function
of mutant p53: R282W on the peak? Oncogenesis, 5, e196.
54. Hammond,E.M. and Giaccia,A.J. (2005) The role of p53 in
hypoxia-induced apoptosis. Biochem. Biophys. Res. Commun., 331,
718–725.
55. Pan,Y., Oprysko,P.R., Asham,A.M., Koch,C.J. and Simon,M.C.
(2004) p53 cannot be induced by hypoxia alone but responds to the
hypoxic microenvironment. Oncogene, 23, 4975–4983.
56. Sermeus,A. and Michiels,C. (2011) Reciprocal influence of the p53
and the hypoxic pathways. Cell Death Dis., 2, e164.
57. Fels,D.R. and Koumenis,C. (2005) HIF-1alpha and p53: the ODD
couple? Trends Biochem. Sci., 30, 426–429.
58. Hammond,E.M. and Giaccia,A.J. (2006) Hypoxia-inducible
factor-1 and p53: friends, acquaintances, or strangers? Clin. Cancer
Res., 12, 5007–5009.
59. Sumiyoshi,Y., Kakeji,Y., Egashira,A., Mizokami,K., Orita,H. and
Maehara,Y. (2006) Overexpression of hypoxia-inducible factor 1
alpha and p53 is a marker for an unfavorable prognosis in gastric
cancer. Clin. Cancer Res., 12, 5112–5117.
60. Amelio,I., Mancini,M., Petrova,V., Cairns,R.A., Vikhreva,P.,
Nicolai,S., Marini,A., Antonov,A.A., Le Quesne,J., Baena
Acevedo,J.D. et al. (2018) p53 mutants cooperate with HIF-1 in
transcriptional regulation of extracellular matrix components to
promote tumor progression. Proc. Natl. Acad. Sci. U.S.A., 115,
E10869–E10878.
61. Hansson,L.O., Friedler,A., Freund,S., Rudiger,S. and Fersht,A.R.
(2002) Two sequence motifs from HIF-1alpha bind to the
DNA-binding site of p53. Proc. Natl. Acad. Sci. U.S.A., 99,
10305–10309.
62. Sanchez-Puig,N., Veprintsev,D.B. and Fersht,A.R. (2005) Binding
of natively unfolded HIF-1alpha ODD domain to p53.Mol. Cell,
17, 11–21.
63. Gogna,R., Madan,E., Kuppusamy,P. and Pati,U. (2012)
Chaperoning of mutant p53 protein by wild-type p53 protein causes
hypoxic tumor regression. J. Biol. Chem., 287, 2907–2914.
64. Koumenis,C., Alarcon,R., Hammond,E., Sutphin,P., Hoffman,W.,
Murphy,M., Derr,J., Taya,Y., Lowe,S.W., Kastan,M. et al. (2001)
Regulation of p53 by hypoxia: Dissociation of transcriptional
repression and apoptosis from p53-dependent transactivation.Mol.
Cell Biol., 21, 1297–1310.
65. Soengas,M.S., Alarcon,R.M., Yoshida,H., Giaccia,A.J., Hakem,R.,
Mak,T.W. and Lowe,S.W. (1999) Apaf-1 and caspase-9 in
p53-dependent apoptosis and tumor inhibition. Science, 284,
156–159.
66. Hammond,E.M., Mandell,D.J., Salim,A., Krieg,A.J., Johnson,T.M.,
Shirazi,H.A., Attardi,L.D. and Giaccia,A.J. (2006) Genome-wide
analysis of p53 under hypoxic conditions.Mol. Cell Biol., 26,
3492–3504.
67. Azhar,G., Liu,L., Zhang,X. and Wei,J.Y. (1999) Influence of age on
hypoxia/reoxygenation-induced DNA fragmentation and bcl-2,
bcl-xl, bax and fas in the rat heart and brain.Mech. Ageing Dev.,
112, 5–25.
68. Chowdhury,A.R., Long,A., Fuchs,S.Y., Rustgi,A. and
Avadhani,N.G. (2017) Mitochondrial stress-induced p53 attenuates
HIF-1alpha activity by physical association and enhanced
ubiquitination. Oncogene, 36, 397–409.
69. Denko,N.C., Green,S.L., Edwards,D. and Giaccia,A.J. (2000) p53
checkpoint-defective cells are sensitive to X rays, but not hypoxia.
Exp. Cell Res., 258, 82–91.
70. Tamatani,M., Mitsuda,N., Matsuzaki,H., Okado,H., Miyake,S.,
Vitek,M.P., Yamaguchi,A. and Tohyama,M. (2000) A pathway of
neuronal apoptosis induced by hypoxia/reoxygenation: roles of
nuclear factor-kappaB and Bcl-2. J. Neurochem., 75, 683–693.
71. Kim,C.Y., Tsai,M.H., Osmanian,C., Graeber,T.G., Lee,J.E.,
Giffard,R.G., DiPaolo,J.A., Peehl,D.M. and Giaccia,A.J. (1997)
Selection of human cervical epithelial cells that possess reduced
apoptotic potential to low-oxygen conditions. Cancer Res., 57,
4200–4204.
72. Muz,B., de la Puente,P., Azab,F. and Azab,A.K. (2015) The role of
hypoxia in cancer progression, angiogenesis, metastasis, and
resistance to therapy. Hypoxia (Auckl), 3, 83–92.
73. Petrova,V., Annicchiarico-Petruzzelli,M., Melino,G. and Amelio,I.
(2018) The hypoxic tumour microenvironment. Oncogenesis, 7, 10.
74. Hockel,M. and Vaupel,P. (2001) Tumor hypoxia: definitions and
current clinical, biologic, and molecular aspects. J. Natl. Cancer
Inst., 93, 266–276.
75. Rankin,E.B. and Giaccia,A.J. (2016) Hypoxic control of metastasis.
Science, 352, 175–180.
76. Wenger,R.H., Kurtcuoglu,V., Scholz,C.C., Marti,H.H. and
Hoogewijs,D. (2015) Frequently asked questions in hypoxia
research. Hypoxia (Auckl), 3, 35–43.
77. Vengellur,A. and LaPres,J.J. (2004) The role of hypoxia inducible
factor 1alpha in cobalt chloride induced cell death in mouse
embryonic fibroblasts. Toxicol. Sci., 82, 638–646.
78. Lopez-Sanchez,L.M., Jimenez,C., Valverde,A., Hernandez,V.,
Penarando,J., Martinez,A., Lopez-Pedrera,C.,
Munoz-Castaneda,J.R., De la Haba-Rodriguez,J.R., Aranda,E.
et al. (2014) CoCl2, a mimic of hypoxia, induces formation of
polyploid giant cells with stem characteristics in colon cancer. PLoS
One, 9, e99143.
79. Dai,Z.J., Gao,J., Ma,X.B., Yan,K., Liu,X.X., Kang,H.F., Ji,Z.Z.,
Guan,H.T. and Wang,X.J. (2012) Up-regulation of hypoxia
inducible factor-1alpha by cobalt chloride correlates with
proliferation and apoptosis in PC-2 cells. J. Exp. Clin. Cancer Res.,
31, 28.
80. Guo,M., Song,L.P., Jiang,Y., Liu,W., Yu,Y. and Chen,G.Q. (2006)
Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce
leukemic cell apoptosis through different hypoxia-inducible
factor-1alpha independent mechanisms. Apoptosis, 11, 67–77.
81. Klumpen,E., Hoffschroer,N., Zeis,B., Gigengack,U., Dohmen,E.
and Paul,R.J. (2017) Reactive oxygen species (ROS) and the heat
stress response of Daphnia pulex: ROS-mediated activation of
hypoxia-inducible factor 1 (HIF-1) and heat shock factor 1 (HSF-1)
and the clustered expression of stress genes. Biol. Cell., 109, 39–64.
82. Chi,J.T., Wang,Z., Nuyten,D.S., Rodriguez,E.H., Schaner,M.E.,
Salim,A., Wang,Y., Kristensen,G.B., Helland,A.,
Borresen-Dale,A.L. et al. (2006) Gene expression programs in
response to hypoxia: cell type specificity and prognostic significance
in human cancers. PLoS Med., 3, e47.
83. Jogi,A., Ora,I., Nilsson,H., Lindeheim,A., Makino,Y., Poellinger,L.,
Axelson,H. and Pahlman,S. (2002) Hypoxia alters gene expression
in human neuroblastoma cells toward an immature and neural
crest-like phenotype. Proc. Natl. Acad. Sci. U.S.A., 99, 7021–7026.
84. Bratasz,A., Pandian,R.P., Deng,Y., Petryakov,S., Grecula,J.C.,
Gupta,N. and Kuppusamy,P. (2007) In vivo imaging of changes in
tumor oxygenation during growth and after treatment.Magn.
Reson. Med., 57, 950–959.
85. Madan,E., Parker,T.M., Bauer,M.R., Dhiman,A., Pelham,C.J.,
Nagane,M., Kuppusamy,M.L., Holmes,M., Holmes,T.R., Shaik,K.
et al. (2018) The curcumin analog HO-3867 selectively kills cancer
cells by converting mutant p53 protein to transcriptionally active
wildtype p53. J. Biol. Chem., 293, 4262–4276.
86. Xia,X.B., Lemieux,M.E., Li,W., Carroll,J.S., Brown,M., Liu,X.S.
and Kung,A.L. (2009) Integrative analysis of HIF binding and
transactivation reveals its role in maintaining histone methylation
homeostasis. Proc. Natl. Acad. Sci. U.S.A., 106, 4260–4265.
87. Schindl,M., Bachtiary,B., Dreier,B., Birner,P., Latinovic,L.,
Karner,B., Breitenecker,G. and Oberhuber,G. (2001) Impact of
human papillomavirus infection on the expression of the KAI1
10234 Nucleic Acids Research, 2019, Vol. 47, No. 19
metastasis suppressor protein in invasive cervical cancer. Cancer
Lett., 162, 261–266.
88. Sharma,A.K., Ali,A., Gogna,R., Singh,A.K. and Pati,U. (2009) p53
Amino-terminus region (1-125) stabilizes and restores heat
denatured p53 wild phenotype. PLoS One, 4, e7159.
89. Madan,E., Pelham,C.J., Nagane,M., Parker,T.M.,
Canas-Marques,R., Fazio,K., Shaik,K., Yuan,Y., Henriques,V.,
Galzerano,A. et al. (2019) Flower isoforms promote competitive
growth in cancer. Nature, 572, 260–264.
90. Madan,E., Gogna,R., Kuppusamy,P., Bhatt,M., Pati,U. and
Mahdi,A.A. (2012) TIGAR induces p53-mediated cell-cycle arrest
by regulation of RB-E2F1 complex. Br. J. Cancer, 107, 516–526.
91. Shieh,S.Y., Ikeda,M., Taya,Y. and Prives,C. (1997) DNA
damage-induced phosphorylation of p53 alleviates inhibition by
MDM2. Cell, 91, 325–334.
92. Thomas,M.C. and Chiang,C.M. (2005) E6 oncoprotein represses
p53-dependent gene activation via inhibition of protein acetylation
independently of inducing p53 degradation.Mol. Cell, 17, 251–264.
93. Gogna,R., Madan,E., Khan,M., Pati,U. and Kuppusamy,P. (2013)
p53′s choice of myocardial death or survival: Oxygen protects infarct
myocardium by recruiting p53 on NOS3 promoter through
regulation of p53-Lys(118) acetylation. EMBOMol. Med., 5,
1662–1683.
94. An,W.G., Kanekal,M., Simon,M.C., Maltepe,E.,
Blagosklonny,M.V. and Neckers,L.M. (1998) Stabilization of
wild-type p53 by hypoxia-inducible factor 1alpha. Nature, 392,
405–408.
95. Baugh,E.H., Ke,H., Levine,A.J., Bonneau,R.A. and Chan,C.S.
(2018) Why are there hotspot mutations in the TP53 gene in human
cancers? Cell Death Differ., 25, 154–160.
96. Cole,A.J., Zhu,Y., Dwight,T., Yu,B., Dickson,K.A., Gard,G.B.,
Maidens,J., Valmadre,S., Gill,A.J., Clifton-Bligh,R. et al. (2017)
Comprehensive analyses of somatic TP53 mutation in tumors with
variable mutant allele frequency. Sci. Data, 4, 170120.
97. Wang,X. and Sun,Q. (2017) TP53 mutations, expression and
interaction networks in human cancers. Oncotarget, 8, 624–643.
98. Forsythe,J.A., Jiang,B.H., Iyer,N.V., Agani,F., Leung,S.W.,
Koos,R.D. and Semenza,G.L. (1996) Activation of vascular
endothelial growth factor gene transcription by hypoxia-inducible
factor 1.Mol. Cell Biol., 16, 4604–4613.
99. Cartharius,K., Frech,K., Grote,K., Klocke,B., Haltmeier,M.,
Klingenhoff,A., Frisch,M., Bayerlein,M. and Werner,T. (2005)
MatInspector and beyond: promoter analysis based on transcription
factor binding sites. Bioinformatics, 21, 2933–2942.
100. Natan,E., Baloglu,C., Pagel,K., Freund,S.M., Morgner,N.,
Robinson,C.V., Fersht,A.R. and Joerger,A.C. (2011) Interaction of
the p53 DNA-binding domain with its n-terminal extension
modulates the stability of the p53 tetramer. J. Mol. Biol., 409,
358–368.
101. Ortiz-Barahona,A., Villar,D., Pescador,N., Amigo,J. and del
Peso,L. (2010) Genome-wide identification of hypoxia-inducible
factor binding sites and target genes by a probabilistic model
integrating transcription-profiling data and in silico binding site
prediction. Nucleic Acids Res., 38, 2332–2345.
102. Mole,D.R., Blancher,C., Copley,R.R., Pollard,P.J., Gleadle,J.M.,
Ragoussis,J. and Ratcliffe,P.J. (2009) Genome-wide Association of
Hypoxia-inducible Factor (HIF)-1 alpha and HIF-2 alpha DNA
binding with expression profiling of Hypoxia-inducible Transcripts.
J. Biol. Chem., 284, 16767–16775.
103. Theodoropoulos,V.E., Lazaris,A.C., Kastriotis,I., Spiliadi,C.,
Theodoropoulos,G.E., Tsoukala,V., Patsouris,E. and Sofras,F.
(2005) Evaluation of hypoxia-inducible factor 1 alpha
overexpression as a predictor of tumour recurrence and progression
in superficial urothelial bladder carcinoma. BJU Int., 95, 425–431.
104. Liu,L., Zhang,P., Bai,M., He,L., Zhang,L., Liu,T., Yang,Z.,
Duan,M., Liu,M., Liu,B. et al. (2018) p53 upregulated by
HIF-1alpha promotes hypoxia-induced G2/M arrest and renal
fibrosis in vitro and in vivo. J. Mol. Cell Biol., 11, 371–382.
105. Zhou,C.H., Zhang,X.P., Liu,F. and Wang,W. (2015) Modeling the
interplay between the HIF-1 and p53 pathways in hypoxia. Sci. Rep.,
5, 13834.
106. Chen,B.S., Longtine,M.S., Sadovsky,Y. and Nelson,D.M. (2010)
Hypoxia downregulates p53 but induces apoptosis and enhances
expression of BAD in cultures of human syncytiotrophoblasts. Am.
J. Physiol.-Cell Ph, 299, C968–C976.
107. Ashcroft,M., Taya,Y. and Vousden,K.H. (2000) Stress signals utilize
multiple pathways to stabilize p53.Mol. Cell Biol., 20, 3224–3233.
108. Suzuki,H., Tomida,A. and Tsuruo,T. (2001) Dephosphorylated
hypoxia-inducible factor 1 alpha as a mediator of p53-dependent
apoptosis during hypoxia. Oncogene, 20, 5779–5788.
109. Anderson,C.W. and Appella,E. (2010) In: Bradshaw,R.A. and
Dennis,E.A. (eds). Handbook of Cell Signaling (Second Edition).
Academic Press, San Diego, pp. 2185–2204.
110. Cooks,T., Pateras,I.S., Tarcic,O., Solomon,H., Schetter,A.J.,
Wilder,S., Lozano,G., Pikarsky,E., Forshew,T., Rosenfeld,N. et al.
(2013) Mutant p53 Prolongs NF-kappa B activation and promotes
chronic inflammation and Inflammation-associated colorectal
cancer. Cancer Cell, 24, 272–272.
111. Dong,P., Karaayvaz,M., Jia,N., Kaneuchi,M., Hamada,J.,
Watari,H., Sudo,S., Ju,J. and Sakuragi,N. (2013) Mutant p53
gain-of-function induces epithelial-mesenchymal transition through
modulation of the miR-130b-ZEB1 axis. Oncogene, 32, 3286–3295.
112. Staller,P., Sulitkova,J., Lisztwan,J., Moch,H., Oakeley,E.J. and
Krek,W. (2003) Chemokine receptor CXCR4 downregulated by von
Hippel-Lindau tumour suppressor pVHL. Nature, 425, 307–311.
113. Maxwell,P.H., Wiesener,M.S., Chang,G.W., Clifford,S.C.,
Vaux,E.C., Cockman,M.E., Wykoff,C.C., Pugh,C.W., Maher,E.R.
and Ratcliffe,P.J. (1999) The tumour suppressor protein VHL targets
hypoxia-inducible factors for oxygen-dependent proteolysis. Nature,
399, 271–275.
114. Iliopoulos,O., Ohh,M. and Kaelin,W.G. Jr. (1998) pVHL19 is a
biologically active product of the von Hippel-Lindau gene arising
from internal translation initiation. Proc. Natl. Acad. Sci. U.S.A.,
95, 11661–11666.
115. Schito,L., Rey,S., Tafani,M., Zhang,H., Wong,C.C., Russo,A.,
Russo,M.A. and Semenza,G.L. (2012) Hypoxia-inducible factor
1-dependent expression of platelet-derived growth factor B
promotes lymphatic metastasis of hypoxic breast cancer cells. Proc.
Natl. Acad. Sci. U.S.A., 109, E2707–E2716.
116. Kotch,L.E., Iyer,N.V., Laughner,E. and Semenza,G.L. (1999)
Defective vascularization of HIF-1alpha-null embryos is not
associated with VEGF deficiency but with mesenchymal cell death.
Dev. Biol., 209, 254–267.
117. Yu,A.Y., Shimoda,L.A., Iyer,N.V., Huso,D.L., Sun,X.,
McWilliams,R., Beaty,T., Sham,J.S., Wiener,C.M., Sylvester,J.T.
et al. (1999) Impaired physiological responses to chronic hypoxia in
mice partially deficient for hypoxia-inducible factor 1alpha. J. Clin.
Invest., 103, 691–696.
118. Wang,Y., Wan,C., Deng,L., Liu,X., Cao,X., Gilbert,S.R.,
Bouxsein,M.L., Faugere,M.C., Guldberg,R.E., Gerstenfeld,L.C.
et al. (2007) The hypoxia-inducible factor alpha pathway couples
angiogenesis to osteogenesis during skeletal development. J. Clin.
Invest., 117, 1616–1626.
119. Zehetner,J., Danzer,C., Collins,S., Eckhardt,K., Gerber,P.A.,
Ballschmieter,P., Galvanovskis,J., Shimomura,K., Ashcroft,F.M.,
Thorens,B. et al. (2008) PVHL is a regulator of glucose metabolism
and insulin secretion in pancreatic beta cells. Genes Dev., 22,
3135–3146.
120. Cramer,T., Yamanishi,Y., Clausen,B.E., Forster,I., Pawlinski,R.,
Mackman,N., Haase,V.H., Jaenisch,R., Corr,M., Nizet,V. et al.
(2003) HIF-1alpha is essential for myeloid cell-mediated
inflammation. Cell, 112, 645–657.
121. Bohuslavova,R., Cerychova,R., Papousek,F., Olejnickova,V.,
Bartos,M., Go¨rlach,A., Kolar,F., Sedmera,D., Semenza,G.L. and
Pavlinkova,G. (2019) HIF-1 is required for development of the
sympathetic nervous system. Proc. Natl. Acad. Sci. U.S.A., 116,
13414–13423.
122. Sano,M., Minamino,T., Toko,H., Miyauchi,H., Orimo,M., Qin,Y.,
Akazawa,H., Tateno,K., Kayama,Y., Harada,M. et al. (2007)
p53-induced inhibition of Hif-1 causes cardiac dysfunction during
pressure overload. Nature, 446, 444–448.
